Guidance for Industry
Botanical Drug Products

U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
June 2004

Chemistry
Guidance for Industry

Botanical Drug Products

Copies of this Guidance are available from:

Division of Drug Information (HFD-240),
Office of Training and Communications,
Center for Drug Evaluation and Research (CDER),
Food and Drug Administration
5600 Fishers Lane, Rockville, MD 20857, (Tel) 301-827-4573

Internet at http://www.fda.gov/cder/guidance/index.htm

U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
June 2004

Chemistry
TABLE OF CONTENTS

I. INTRODUCTION .......................................................................................................................... 1

II. BACKGROUND ............................................................................................................................ 2

III. GENERAL REGULATORY APPROACHES .............................................................................. 3
   A. Marketing Under OTC Drug Monograph Versus Approved NDA ........................................... 4
   B. CMC Information for Botanical Drug Products ........................................................................... 5
   C. CMC and Toxicology Information to Support Initial Studies ................................................ 5
   D. Applicability of Combination Drug Regulations ................................................................. 6

IV. MARKETING A BOTANICAL DRUG UNDER AN OTC DRUG MONOGRAPH ..... 6

V. MARKETING A BOTANICAL DRUG UNDER AN NDA .................................................... 7

VI. INDs FOR BOTANICAL DRUGS .......................................................................................... 7
   A. IND Information for Different Categories of Botanicals ......................................................... 7
   B. Basic Format for INDs ............................................................................................................. 9
      1. Cover Sheet (see § 312.23(a)(1)) ..................................................................................... 9
      2. Table of Contents (see § 312.23(a)(2)) ............................................................................. 9
      3. Introductory Statement and General Investigational Plan (see § 312.23(a)(3)) .................. 9
      4. Investigator’s Brochure (see § 312.23(a)(5)) ................................................................... 9
      5. Protocols (§ 312.23(a)(6)) ............................................................................................ 9
      6. Chemistry, Manufacturing, and Controls (§ 312.23(a)(7)) ................................................. 10
      7. Pharmacological and Toxicological Information (§ 312.23(a)(8)) ..................................... 13
      8. Previous Human Experience With the Product (§ 312.23(a)(9)) ...................................... 13

VII. INDs FOR PHASE 1 AND PHASE 2 CLINICAL STUDIES OF LAWFULLY MARKETED BOTANICAL PRODUCTS WITHOUT SAFETY CONCERNS .......... 13
   A. Description of Product and Documentation of Human Use .................................................. 13
      1. Description of Botanicals Used (§ 312.23(a)(3)(i)) ......................................................... 14
      2. History of Use (§ 312.23(a)(3)(ii), (a)(9)) ......................................................................... 14
      3. Current Marketed Use (§ 312.23(a)(3)(ii), (a)(9)) ....................................................... 14
   B. Chemistry, Manufacturing, and Controls .............................................................................. 14
      1. Botanical Raw Material (§ 312.23(a)(7)(i)) ................................................................. 14
      2. Botanical Drug Substance (§ 312.23(a)(7)(iv)(a)) ......................................................... 15
      3. Botanical Drug Product (§ 312.23(a)(7)(iv)(b)) .......................................................... 15
      4. Animal Safety Test (§ 312.23(a)(8)) ................................................................................ 16
      5. Placebo (§ 312.23(a)(7)(iv)(c)) ..................................................................................... 16
      6. Labeling (§ 312.23(a)(7)(iv)(d)) ..................................................................................... 16
      7. Environmental Assessment or Claim of Categorical Exclusion (§ 312.23(a)(7)(iv)(e)) ...... 17
   C. Pharmacology/Toxicology Information .................................................................................... 17
      1. All Marketed Botanical Products ...................................................................................... 17
      2. Foreign-Marketed Botanical Products .............................................................................. 18
   D. Bioavailability ......................................................................................................................... 18
   E. Clinical Considerations ........................................................................................................... 18
VIII. INDS FOR PHASE 1 AND PHASE 2 CLINICAL STUDIES FOR NONMARKETED BOTANICAL PRODUCTS AND PRODUCTS WITH KNOWN SAFETY CONCERNS ............................................................................................................... 19

A. Description of Product and Documentation of Human Use................................................................. 19
   1. Description of Botanicals Used (§ 312.23(a)(3)(i))........................................................................... 19
   2. History of Use (If Any) (§ 312.23(a)(3)(ii), (a)(9))........................................................................ 19
   3. Current Investigational Use (If Any) (§ 312.23(a)(3)(ii), (a)(9)).................................................... 20

B. Chemistry, Manufacturing, and Controls ............................................................................................ 20
   1. Botanical Raw Material (§ 312.23(a)(7)(i)) ................................................................................... 20
   2. Botanical Drug Substance (§ 312.23(a)(7)(iv)(a)) ........................................................................ 21
   3. Botanical Drug Product (§ 312.23(a)(7)(iv)(b)) ........................................................................... 23
   4. Placebo (see section VII.B.5)............................................................................................................ 25
   5. Labeling (see section VII.B.6)............................................................................................................ 25
   6. Environmental Assessment or Claim of Categorical Exclusion ...................................................... 25

C. Nonclinical Safety Assessment ........................................................................................................... 25
   1. Traditional Preparations .................................................................................................................. 25
   2. Others.................................................................................................................................................. 26
   3. Products with Known Safety Issues ................................................................................................. 26

D. Bioavailability....................................................................................................................................... 26

E. Clinical Considerations ........................................................................................................................ 27

IX. INDS FOR PHASE 3 CLINICAL STUDIES OF ALL BOTANICAL PRODUCTS ... 27

A. Description of Product and Documentation of Human Experience.................................................. 27

B. Chemistry, Manufacturing, and Controls ............................................................................................ 28
   1. Expanded Clinical Studies ................................................................................................................ 28
   2. End-of-Phase 3 Clinical Studies and Pre-NDA Considerations....................................................... 32

C. Nonclinical Safety Assessment .......................................................................................................... 34
   1. Repeat-Dose General Toxicity Studies ............................................................................................ 35
   2. Nonclinical Pharmacokinetic/Toxicokinetic Studies ....................................................................... 35
   3. Reproductive Toxicology ................................................................................................................. 36
   4. Genotoxicity Studies ........................................................................................................................ 36
   5. Carcinogenicity Studies .................................................................................................................. 36
   6. Special Pharmacology/Toxicology Studies ....................................................................................... 37
   7. Regulatory Considerations .............................................................................................................. 37

D. Bioavailability and Clinical Pharmacology .......................................................................................... 37

E. Clinical Considerations ....................................................................................................................... 38

GLOSSARY.................................................................................................................................................. 39

QUESTIONS AND ANSWERS .................................................................................................................. 42

ATTACHMENT A: REGULATORY APPROACHES FOR MARKETING BOTANICAL DRUG PRODUCTS ................................................................................................................. 47
This guidance represents the Food and Drug Administration’s (FDA’s) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the FDA staff responsible for implementing this guidance. If you cannot identify the appropriate FDA staff, call the appropriate number listed on the title page of this guidance.

I. INTRODUCTION

This guidance explains when a botanical drug may be marketed under an over-the-counter (OTC) drug monograph and when FDA regulations require approval for marketing of a new drug application (NDA), submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. 355(b). In addition, this document provides sponsors with guidance on submitting investigational new drug applications (INDs) for botanical drug products, including those botanical products (or botanicals) currently lawfully marketed as foods (including conventional foods and dietary supplements) in the United States.

This guidance also discusses several areas in which, because of the unique nature of botanicals, FDA finds it appropriate to apply regulatory policies that differ from those applied to synthetic, semisynthetic, or otherwise highly purified or chemically modified drugs (including antibiotics derived from microorganisms). This latter group of drug substances is referred to in this guidance as synthetic or highly purified drugs. Therefore, when the recommendations on a specific topic discussed in this guidance differ from those in other existing guidances (e.g., Submitting Supporting Documentation in Drug Applications for the Manufacture of Drug Substances, 1987),2 this guidance takes precedence. In particular, this guidance states that applicants may submit reduced documentation of nonclinical (preclinical) safety and of chemistry, manufacturing, and controls (CMC) to support an IND for initial clinical studies of

---

1 This guidance has been prepared by working groups in the Medical Policy, Pharmacology and Toxicology, and Complex Drug Substances Coordinating Committees in the Center for Drug Evaluation and Research (CDER) at the Food and Drug Administration (FDA).

2 FDA has issued a draft guidance entitled Drug Substance: Chemistry, Manufacturing, and Controls Information, which, when finalized, will replace the 1987 guidance (see 69 FR 929, January 7, 2004).
botanicals that have been legally marketed in the United States and/or a foreign country as dietary supplements without any known safety concerns.

FDA's guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word *should* in Agency guidances means that something is suggested or recommended, but not required.

II. BACKGROUND

*Botanical products* are finished, labeled products that contain vegetable matter as ingredients.\(^3\) A botanical product may be a food (including a dietary supplement), a drug (including a biological drug), a medical device (e.g., gutta-percha), or a cosmetic under the Act. An article is generally a food if it is used for food (21 U.S.C. 312(f)(1)). Whether an article is a drug, medical device, or cosmetic under the Act turns on its “intended use” (21 U.S.C. 312(g)(1)(B) and (C), (h)(2) and (3), (i)). “Intended use” is created by claims made by or on behalf of a manufacturer or distributor of the article to prospective purchasers, such as in advertising, labeling, or oral statements.

For the purposes of this document, the term *botanicals* includes plant materials, algae, macroscopic fungi, and combinations thereof. It does not include:

- Materials derived from genetically modified botanical species (i.e., by recombinant DNA technology or cloning).
- Fermentation products (i.e., products produced by fermentation of yeast, bacteria, and other microscopic organisms, including when plants are used as a substrate, and products produced by fermentation of plant cells), even if such products are previously approved for drug use or accepted for food use in the United States (e.g., antibiotics, amino acids, and vitamins).
- Highly purified substances (e.g., paclitaxel) or chemically modified substances (e.g., estrogens synthesized from yam extracts) derived from botanical sources.

This guidance addresses all botanical drug products (in all dosage forms) that are regulated under the Act, except those also regulated under section 351 of the Public Health Service Act (42 U.S.C. 262). Although this guidance does not address drugs that contain animals or animal parts (e.g., insects, annelids, shark cartilage) and/or minerals, either alone or in combination with botanicals, many scientific principles described in this guidance may also apply to those products. When a drug product contains botanical ingredients in combination with either (1) a synthetic or highly purified drug or (2) a biotechnology derived or other naturally derived drug, this guidance only applies to the botanical portion of the product.

\(^3\) *Botanical product* and other terms used in this guidance are defined in the Glossary for use in this guidance only; these definitions may not be appropriate in other contexts.
III. GENERAL REGULATORY APPROACHES

Many botanical products are used widely in the United States. Depending on its labeling and intended use, a botanical product can be a food, a dietary supplement, and/or a drug. Botanicals used for food and consumed primarily for their taste, aroma, or nutritive value (e.g., lettuce, herbs used as seasonings) are regulated as foods. Botanicals can also be dietary supplements if they are labeled as dietary supplements and otherwise meet the dietary supplement definition in section 201(ff) of the Act (21 U.S.C. 321(ff)).

If a botanical product is intended for use in diagnosing, mitigating, treating, or curing disease, it is a drug under section 201(g)(1)(B) of the Act and is subject to regulation as such. If a botanical product is intended to prevent disease, it is also a drug under section 201(g)(1)(B), except that a product that bears a health claim authorized in accordance with section 403(r) of the Act (21 U.S.C. 343(r)) is not a drug solely because its labeling contains such a claim. If the intended use of a botanical product is to affect the structure or function of the human body, it may be regulated either as a dietary supplement or as a drug, depending on the circumstances.

Under the Dietary Supplement Health and Education Act of 1994 (DSHEA), an orally ingested product that meets the definition of a “dietary supplement” under section 201(ff) of the Act may be lawfully marketed with a statement that (1) claims a benefit related to a classical nutrient deficiency disease (and discloses the prevalence of the disease in the United States), (2) describes how the product is intended to affect the structure or function of the human body, (3) characterizes the documented mechanism by which the product acts to maintain such structure or function, or (4) describes general well-being from consumption of the product (section 403(r)(6)(A) of the Act). A dietary supplement statement of the type described above may not claim to diagnose, mitigate, treat, cure, or prevent a specific disease or class of diseases (section 403(r)(6) of the Act).

If a botanical product is intended to affect the structure or function of the body but does not meet the definition of a dietary supplement, or does not meet the requirements for making a structure/function claim under section 403(r)(6) of the Act, it is subject to regulation as a drug under section 201(g)(1)(C) of the Act. As noted above, a botanical product is subject to regulation as a drug under section 201(g)(1)(B) of the Act if it is intended for use in diagnosing, mitigating, treating, curing, or preventing disease (except for a product marketed with certain health claims authorized under section 403(r) of the Act). Under section 505(b) of the Act, a

4The manufacturer must have substantiation that such statement is truthful and not misleading (section 403(r)(6)(B) of the Act) and must notify FDA that the statement is being used no later than 30 days after the first marketing of the dietary supplement with the statement (section 403(r)(6) of the Act). In addition, the statement must be accompanied by the following disclaimer: “This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease” (section 403(r)(6)(C) of the Act). FDA regulations at 21 CFR 101.93(b)-(e) prescribe the required format and placement of the disclaimer in dietary supplement labeling.

5FDA regulations at § 101.93(g) define disease for purposes of this provision and set forth what types of statements FDA will consider to be claims to diagnose, mitigate, treat, cure, or prevent disease.
drug must be marketed under an approved NDA unless the product is excluded from the definition of a new drug under section 201(p) of the Act. Certain products that FDA determines are generally recognized as safe and effective in accordance with section 201(p) may be marketed under FDA’s OTC drug monograph system.

A. Marketing Under OTC Drug Monograph Versus Approved NDA

A botanical drug product may be marketed in the United States under (1) an OTC drug monograph or (2) an approved NDA or ANDA. A botanical product that has been marketed in the United States for a material time and to a material extent for a specific OTC drug indication may be eligible for inclusion in an OTC drug monograph codified in 21 CFR parts 331-358. The manufacturer would need to submit a petition in accordance with 21 CFR 10.30 to amend the monograph to add the botanical substance as a new active ingredient.

Under current regulations, if there is no marketing history in the United States or a foreign country for a botanical drug product, if available evidence of safety and effectiveness does not warrant inclusion of the product in an OTC drug monograph, or if the proposed indication would not be appropriate for nonprescription use, the manufacturer must submit an NDA to obtain FDA approval to market the product for the proposed use (sections 201(p) and 505 of the Act). An NDA for a botanical drug could seek approval for either prescription or OTC use, depending on the indication and characteristics of the product and whether it is safe for use outside of the supervision of a practitioner licensed by law to administer it. If existing information on the safety and effectiveness of a botanical drug product is insufficient to support an NDA, we recommend that new clinical studies be conducted to demonstrate safety and effectiveness.

When a final OTC drug monograph is published for a specific use of a botanical drug, any person may market a product containing the same substance and for the same use, provided the labeling and other active ingredients (if present) are in accord with all relevant monographs and other applicable regulations. In contrast, when a product is approved under an NDA, the approval is specific to the drug product that is the subject of the application (the applicant’s drug product), and the applicant may be eligible for

---

6. Under section 505(j) of the Act, a botanical drug product may also be marketed as a generic drug under an abbreviated new drug application (ANDA). The generic version of the previously approved drug would have to be both pharmaceutically equivalent and bioequivalent to such drug. For information on the submission of ANDAs, see FDA regulations in 21 CFR parts 314 and 320 as well as Agency guidance documents.

7. FDA has issued a final rule that establishes criteria and procedures by which conditions may become eligible for inclusion in the OTC drug monograph system (67 FR 3060, January 23, 2002). Among other things, the final rule addresses how FDA considers foreign marketing data in determining whether a drug has been used under particular conditions to a material extent and for a material time (as required under section 201(p) of the Act) to qualify for inclusion in an OTC drug monograph.

8. See 21 CFR 312.20 (concerning requirement for an IND).
marketing exclusivity for either 5 years (if it is a new chemical entity) or 3 years from the
time of approval, even in the absence of patent protection. A new botanical drug
(containing multiple chemical constituents) may qualify as a new chemical entity under
§ 314.108(a). If a product qualifies as a new chemical entity, during the period of
exclusivity, FDA will not approve, or in some cases even review, certain competitor
products unless the second sponsor conducts all studies necessary to demonstrate the
safety and effectiveness of its product and submits a 505(b)(1) application. Therefore, if
a person wishing to market a botanical drug product that is not included in an existing
OTC drug monograph desires marketing exclusivity for the product, the person should
seek approval of an NDA rather than petition the Agency to amend a monograph.
Attachment A contains a schematic showing different regulatory approaches that can be
taken for marketing botanical drug products in the United States, including OTC drug
monograph and NDA procedures.

B. CMC Information for Botanical Drug Products

Botanical drug products have certain unique characteristics that should be taken into
account in the application of FDA regulations and guidance. Botanical drugs are derived
from vegetable matter and are usually prepared as complex mixtures. Their chemical
constituents are not always well defined. In many cases, the active constituent in a
botanical drug is not identified, nor is its biological activity well characterized.
Therefore, the CMC documentation that should be provided for botanical drugs will often
be different from that for synthetic or highly purified drugs, whose active constituents can
be more readily chemically identified and quantified. For example, FDA would expect an
NDA for a synthetic or highly purified drug to identify the active ingredient. However, it
would not be essential for the sponsor of a botanical drug to identify the active
constituents (although FDA recommends that this be done if feasible). Even if the
sponsor were to eventually identify the active constituents in the NDA, the active
constituents might not be identified during the IND stage.

Because of the complex nature of a typical botanical drug and the lack of knowledge of its
active constituent(s), FDA may rely on a combination of tests and controls to ensure the
identity, purity, quality, strength, potency, and consistency of botanical drugs. These tests
and controls include (1) multiple tests for drug substance and drug product (e.g.,
spectroscopic and/or chromatographic fingerprints, chemical assay of characteristic
markers, and biological assay), (2) raw material and process controls (e.g., strict quality
controls for the botanical raw materials and adequate in-process controls), and (3) process
validation (especially for the drug substance).

C. CMC and Toxicology Information to Support Initial Studies

Many botanical products are legally available in the United States as dietary
supplements. Given the wide availability of such products outside of clinical trials, it is
important to assess the effectiveness of such products. To support initial clinical trials,
the nonclinical pharmacology and toxicology information that must be provided under 21
CFR 312.22(b) for legally available botanical products with no known safety issues (see
Contains Nonbinding Recommendations

section VI.A) may be markedly reduced compared to that expected for synthetic or highly purified new drugs that are not legally marketed and for which there is no prior human experience. In most cases, additional toxicology and CMC data will not be required for such initial trials.

D. Applicability of Combination Drug Regulations

Botanical drug products that are derived from a single part of a plant (e.g., leaves, stems, roots, or seeds), or from a single species of alga or macroscopic fungus (e.g., a mushroom), are not considered to be fixed-combination drugs within the meaning of 21 CFR 300.50 and 330.10(a)(4)(iv). Consequently, they do not have to meet the requirements for combination drugs, principally the need to demonstrate that each component or active ingredient makes a contribution to claimed effects.

Botanical drugs composed of multiple parts of a single species of plant, alga, or macroscopic fungus, or of parts from different species of plants algae, or macroscopic fungi, currently are subject to the combination drug requirements. However, FDA is considering revising its regulations to allow for the exemption of such botanical drugs from application of the combination drug requirements under certain circumstances.

IV. MARKETING A BOTANICAL DRUG UNDER AN OTC DRUG MONOGRAPH

A botanical product that has been marketed in the United States for a material time and to a material extent for a specific OTC indication may be eligible for consideration in the OTC drug monograph system. Currently, there are several botanical drugs, including cascara, psyllium, and senna, that are included in the OTC drug review. For a botanical drug substance to be included in an OTC drug monograph, there must be published data establishing general recognition of safety and effectiveness, usually including results of adequate and well-controlled clinical studies (see §§ 314.126(b) and 330.10). Requirements related to safety, effectiveness, and labeling for drugs to be included in an OTC drug monograph are set forth in 21 CFR part 330.

A request to amend an OTC drug monograph to include a botanical substance must be submitted by citizen petition in accordance with §§ 10.30 and 330.10(a)(12). There should be publicly available quality standards for such a botanical drug substance in the drug section (i.e., not in the National Formulary or other nondrug sections) of the United States Pharmacopeia (USP). In the absence of a USP drug monograph, the petitioner should include suitable quality standards for the botanical drug substance in its citizen petition and simultaneously propose adoption of those standards in the USP. Additional criteria and procedures by which a botanical drug substance may become eligible for inclusion in the OTC drug monograph system are set forth in § 330.14. FDA regulations on current good manufacturing practices (CGMPs) apply to all OTC drug monograph products, including any listed botanical drug products (see § 330.1(a)).

However, a botanical drug’s conformance to the standards of the USP or any other official compendium does not establish that the botanical is safe, effective, and not misbranded for its intended use as a drug.

9
For further information on the OTC drug monograph approach to marketing a botanical drug product, sponsors are encouraged to contact CDER's Division of Over-the-Counter Drug Products (HFD-560).

V. MARKETING A BOTANICAL DRUG UNDER AN NDA

A botanical drug product that is not generally recognized as safe and effective for its therapeutic claims is considered a new drug under section 201(p) of the Act. Section 505(a) of the Act requires any person wishing to market a botanical drug product that is a new drug to obtain FDA approval of an NDA or ANDA for that product. According to section 505(d) of the Act and § 314.50, an NDA must contain substantial evidence of effectiveness derived from adequate and well-controlled clinical studies, evidence of safety, and adequate CMC information. The format of an NDA submission and the requirements for its various sections are set forth in part 314 and discussed in several CDER guidance documents.

VI. INDS FOR BOTANICAL DRUGS

If available information is insufficient to support an NDA for a botanical drug, the sponsor will need to develop further data. An IND is required under section 505(i) of the Act and 21 CFR part 312 (unless exempt under § 312.2(b)) when a botanical product is studied in the United States for a drug use (see section 201(g) of the Act), even if such study is intended solely for research purposes. Under § 312.22, an IND must contain sufficient information to demonstrate that the drug product is safe for testing in humans and that the clinical protocol is properly designed for its intended objectives.

A. IND Information for Different Categories of Botanicals

Under § 312.22(b), the amount of information that must be submitted in an IND for a particular drug product depends on, among other things, the novelty of the drug, the extent to which it has been studied previously, the drug product’s known or suspected risks, and the developmental phase of the drug. Sections VII and VIII of this guidance describe the information that we recommend a sponsor provide in meeting the requirements in § 312.23 for an IND for initial (i.e., phase 1 and phase 2) clinical studies of a botanical drug. As noted above, for botanicals legally marketed under the DSHEA, there will often be very little new CMC or toxicological data needed to initiate such trials, as long as there are no known safety issues associated with the product and it is to be used at approximately the same doses as those currently or traditionally used or recommended. A botanical drug is considered to have a known safety issue when FDA has evidence that it produces serious and/or possibly life-threatening effects. Nonclinical evaluation to characterize toxicities may be appropriate for products with known safety issues. For example, nonclinical data may be appropriate to help establish safe doses and to determine ways to better monitor potential toxicities in humans. Such nonclinical studies may be needed early in development (see § 312.23(a)(8)).
Properly conducted early clinical investigations, including controlled effectiveness trials in phase 2, will allow a determination of whether there is a clinical effect worth pursuing and will provide a more systematic evaluation of safety than previously available. If a botanical drug product shows promise of effectiveness in such early trials, the potential for wider use for particular purposes will create a need for greater assurance of product quality and consistency and for expanded (i.e., phase 3) clinical studies of safety and effectiveness (§ 312.22(b)). IND information appropriate for expanded clinical studies of botanical drugs is discussed in section IX.

Under § 312.22(b), the IND sponsor of a botanical product that has been previously marketed but not in the United States must provide sufficient additional information to assist FDA in determining the safety of the product for use in initial clinical studies (section VII). Such additional information is appropriate under that regulation because these products are not already marketed in the United States and evidence of safety should be provided before patients are exposed to them.

This guidance also addresses the type of information that should be provided under § 312.22 in INDs for initial studies on botanical products that have not been lawfully marketed anywhere or have known safety issues (section VIII). In contrast to botanical products that have been marketed in some form, considerably less information may be available on the safety of a new botanical product that has not been marketed anywhere as a food or dietary supplement and has not been tested as a drug in humans. Consequently, it is appropriate that, under § 312.22(b), sponsors of INDs for initial trials of botanical products that have not previously been lawfully marketed anywhere, or for which there are known safety issues, provide certain additional information to FDA.

The information to be provided in an IND for a botanical drug product is illustrated schematically in Attachment B and discussed in this section and sections VII-IX below. FDA encourages sponsors of INDs for initial studies of botanical drugs to seek input from CDER review divisions (organized based on the therapeutic classes of the drugs) to ensure that the appropriate information is submitted and that the clinical protocols are well designed. Many guidance documents specific to particular indications or dosage forms are also available from the respective review divisions.

FDA may place an IND for initial studies of a botanical drug on clinical hold (i.e., an order issued by the Agency to delay a proposed clinical study) if it finds that the IND does not contain sufficient information required under § 312.23 to assess the risk to subjects of the proposed studies (§ 312.42(b)(1)(iv)). However, the lack of any specific item of information listed in § 312.23 for a phase 1 study will not necessarily justify imposing a clinical hold. Possible grounds for a clinical hold are set forth in § 312.42(b) and discussed in CDER’s guidance for industry on Content and Format of Investigational New Drug Applications (INDs) for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-derived Products (November 1995).
B. Basic Format for INDs

The format and general requirements for IND submissions are stated in § 312.23 and discussed in several CDER guidance documents, including the phase 1 guidance referenced above. These requirements are summarized below, with guidance on the specific types of information that we recommend sponsors of botanical drug products provide to meet these requirements:

1. **Cover Sheet (see § 312.23(a)(1))**

2. **Table of Contents (see § 312.23(a)(2))**

3. **Introductory Statement and General Investigational Plan (see § 312.23(a)(3))**

4. **Investigator’s Brochure (see § 312.23(a)(5))**

5. **Protocols (§ 312.23(a)(6))**

Section 312.23(a)(6) requires information on protocols for planned studies. In general, clinical evaluation of botanical drug products for safety and effectiveness does not differ significantly from evaluation of synthetic or highly purified drugs. For study results to be interpretable, clinical studies must be well designed and carefully executed (see § 314.126). A sponsor need not differentiate the clinical effects of each molecular entity in a botanical product derived from a single part of a plant (see section III.D, Applicability of Combination Drug Regulations). Even where the components of a combination product must be studied under § 300.50, initial controlled studies could be used to evaluate the entire combination product. For additional information on the clinical development of new drugs, see the CDER guidance *Format and Content of the Clinical and Statistical Sections of an Application* (July 1988) and other guidances related to the submission of applications involving specific drug classes and diseases.

Clinical studies of botanical products may pose special problems associated with the incorporation of traditional methodologies, such as selection of doses and addition of new botanical ingredients based on response, that will need to be resolved. In almost all cases, credible studies will be randomized, double blind, and placebo-controlled (or dose-response) (see § 314.126). Studies with only active controls may be appropriate when it is unethical to use a placebo, as would be the case in serious and life-threatening conditions for which there is established effective therapy. However, active studies pose special difficulties in interpretation and should be used only when a placebo cannot be used and there is good reason to expect the botanical treatment to be effective. With respect to serious illnesses for which there is established effective therapy, we generally encourage sponsors to use an “add-on” design for the initial trials: The botanical product would be compared to a placebo, each being added to the standard treatment. For symptomatic disorders where the use of a placebo poses no ethical problem, placebo-controlled trials should almost always be conducted because active control trials are particularly difficult to interpret in such situations. Having a concurrent active treatment
Contains Nonbinding Recommendations

group in addition to placebo control (e.g., a three-armed study) is advisable in certain cases (as in psychiatric trials) to verify the assay sensitivity of the study. The sponsor is encouraged to consult International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guidance E10 Choice of Control Group and Related Issues in Clinical Trials (May 2000).

For botanical as well as for synthetic or highly purified drugs, absolute safety does not exist for any therapeutic intervention, and FDA must assess risks in light of potential clinical benefits (see § 312.22). For more comprehensive information on safety evaluations, see other CDER guidance documents. As is the case for synthetic or highly purified drugs, the best safety data on newly developed botanicals will be derived from controlled efficacy trials, but for chronic indications, long-term, open-label extensions also will be important. For chronic conditions, exposures of at least 6-12 months’ duration are usually appropriate (see ICH guidance E1A The Extent of Population Exposure to Assess Clinical Safety: For Drugs Intended for Long-term Treatment of Non-Life-Threatening Conditions (March 1995)).

Section VII.E of this guidance provides recommendations on the protocol design of initial clinical trials for botanical products legally marketed under the DSHEA. Sections VIII.E and IX.E provide information on the design of initial clinical trials for nonmarketed botanical drug products and for expanded studies on all botanical drug products, respectively.

As with any clinical study, appropriate human research subject protections must be followed, including submission of the protocol to an institutional review board (IRB) and obtaining proper informed consent (see 21 CFR parts 56 and 50). Pursuant to § 50.25, the consent form should describe any procedures that are experimental along with a description of the risks, benefits, and alternatives of taking the product. We recommend that the consent form acknowledge any lack of additional chemical or toxicological characterization.

6. Chemistry, Manufacturing, and Controls (§ 312.23(a)(7))

The requirements for the content and format of the CMC section of an IND are stated in § 312.23(a)(7)(iv)(a)-(e). These regulations require documentation of the drug substance, drug product, placebo, labeling, and an environmental analysis.

Plant materials used in the production of botanical drug products often are not completely characterized and defined or are prone to contamination, deterioration, and variation in composition and properties. In many cases, the active constituent in a botanical drug is not identified, nor is its biological activity well characterized. Therefore, in contrast to the situation with synthetic or highly purified drug products, it may be difficult to ensure the quality of a botanical drug by controlling only the corresponding drug substance and drug product. To ensure that a botanical drug product used in clinical trials is of consistently good quality, and that sufficient information exists to meet the requirements
of § 312.23(a)(7)(iv), the sponsor should have, in addition to final product testing, appropriate quality controls for the botanical raw materials. The manufacturing process should be well defined, with adequate in-process controls, especially for the drug substance.

As noted in section III.C, sponsors of initial clinical trials on botanical products that have been legally marketed as dietary supplements and that do not have safety issues can submit less CMC information than must be provided under §§ 312.22(b) and 312.23(a)(7)) for later studies or for studies on products not previously marketed. Section VII.B describes the CMC information that generally will be necessary under § 312.23(a)(7) for initial trials on previously marketed botanicals without safety issues.

To comply with §§ 312.22(b) and 312.23(a)(7), sponsors must submit additional CMC information for initial studies of nonmarketed botanical products and marketed botanicals with safety issues (see section VIII.B) and for expanded trials on all botanical products (see section IX.B). Additional guidance (not specific to botanical drugs) on the submission of CMC information in INDs and marketing applications can be found in other CDER guidance documents.

In the initial stage of clinical studies of a botanical drug, it is generally not necessary to identify the active constituents or other biological markers or to have a chemical identification and assay for a particular constituent or marker. Identification by spectroscopic and/or chromatographic fingerprinting and strength by dry weight (weight minus water or solvents) can be acceptable alternatives. Attributes for lot or batch release testing should be determined as the clinical study progresses, although appropriate acceptance criteria for batch release need not be established until later in phase 3 studies. Batch analyses on clinical batches should be submitted as they become available, to demonstrate batch-to-batch consistency and to help establish appropriate acceptance criteria for fingerprinting. Identification of active constituents is helpful in optimizing manufacturing procedures, ensuring batch consistency, and contributing to an understanding of the clinical effects of the botanical product. Therefore, when feasible, active constituents should be identified during phase 3 studies.

A single formulation (i.e., one in which the components or ingredients and composition of the drug substance and drug product are kept constant) and a single dosage form should be used throughout the different stages of the clinical trials unless this proves impossible. Screening of a number of sources/batches for product quality is recommended to ensure that the material used in initial trials will yield interpretable results that can be used to guide later development. Once a batch or source of acceptable quality is identified, sufficient quantities should be obtained to sustain the initial clinical trials. This is especially important if the sponsor does not have access to the manufacturing and controls information on the botanical drug substance and finished product. In addition, sufficient quantities of the botanical raw material and drug substance from the same batch should be retained for future chemical characterization and/or pharmacological/toxicological testing. It is also important to obtain the botanical drug product from a source willing to provide FDA with detailed manufacturing and
controls information when needed, or as clinical evaluation of the product progresses. These factors are crucial if the sponsor intends to pursue FDA approval for a new drug application for the botanical product.

Consistency should be maintained when multiple batches are used in the nonclinical and clinical trials. It also is important that the material used in phase 1/2 trials be verified for its authenticity (see VIII.B.1 below). Samples from phase 1/2 studies should be retained for comparison with batches to be used in the phase 3 trials to ensure consistency. Bridging studies (clinical and/or nonclinical) should be performed if the use of batches with different characteristics in different phases cannot be avoided.

Botanical raw materials may sometimes be dispensed at clinics on an as needed or by prescription basis and subsequently prepared by patients themselves at home. We recommend avoiding these practices during clinical trials if at all possible because data related to such use may not be reliable because of variability in preparation by patients. When absolutely necessary, dispensing in such a manner may be considered for initial clinical studies. But as clinical trials are expanded, the botanical drug product should be produced in a controlled manner by an established manufacturer to ensure the validity and reliability of data.

If previously available nonclinical and/or clinical data are provided or referenced in the IND, a comparison should be made of the botanical drug products used in the referenced studies, the products to be used in the proposed trials, and (if appropriate) the products intended for marketing (including their corresponding botanical raw materials, drug substances, and formulations).

If a synthetic or highly purified drug or a biotechnology- or other naturally derived (non-botanical) drug is added to a botanical drug product, the CMC data for this added substance should be described or cross-referenced according to § 312.23(b) and guidances. Under § 312.23(a)(7), animal parts (e.g., insects, annelids, shark cartilage) or minerals that are combined with a botanical in a drug product, must be accompanied by additional manufacturing and controls information specific to these materials because they are part of the drug substance being studied.

CMC information on a botanical raw material, drug substance, and/or drug product may be submitted by the sponsor as part of the IND or by the manufacturer (if different from the sponsor) in a drug master file (DMF). A DMF is a submission from a manufacturer to FDA that may be used to provide confidential information on a human drug (§ 314.420(a)). The information contained in a DMF may be cross-referenced to support an IND or NDA and is reviewed and used by FDA only when authorized by the manufacturer. However, the sponsor relying on information in a DMF should have adequate acceptance testing (e.g., identification test, assay) before accepting the raw material, drug substance, or drug product received from the DMF holder for further processing or for use in humans directly.
7. **Pharmacological and Toxicological Information (§ 312.23(a)(8))**

The content and format for pharmacological and toxicological information to be provided in an IND are described in § 312.23(a)(8). Nonclinical pharmacology and toxicology studies are useful in guiding early clinical studies and in predicting the potential toxicity of a new drug.

Ordinarily, less nonclinical information will be required to support the initial clinical trials of currently marketed orally ingested botanical products than is expected for synthetic or highly purified drugs. For a botanical product that is not currently lawfully marketed in the United States, but is administered orally and prepared, processed, and used according to methodologies for which there is prior human experience, sufficient information may be available to support initial clinical studies without standard nonclinical testing. However, for a botanical drug with a route of administration other than oral, additional pharmacology/toxicology information may be necessary before initial clinical studies.

After initial clinical studies, further pharmacology and toxicology studies of a botanical drug generally would be needed before later phases of clinical development and before approval for marketing. Sections VII.C, VIII.C, and IX.C provide details on the pharmacological and toxicological information that should be provided for clinical trials on botanical drugs.

8. **Previous Human Experience With the Product (§ 312.23(a)(9))**

Under § 312.23(a)(9), an IND sponsor must submit information about previous human experience with an investigational drug. Many botanical products have been marketed or tested in clinical studies (often involving few patients). When such studies have been conducted, data from the studies must be included in an IND for a botanical drug to assist FDA in its overall safety assessment. Sections VII.A, VIII.A, and IX.A of this guidance provide additional recommendations on the submission of information on previous human experience with a botanical product.

**VII. INDS FOR PHASE 1 AND PHASE 2 CLINICAL STUDIES OF LAWFULLY MARKETED BOTANICAL PRODUCTS WITHOUT SAFETY CONCERNS**

This section provides more detailed guidance on the submission of certain types of information for INDs for initial clinical studies on botanical products that have been lawfully marketed and that do not raise safety issues (for drugs with known safety concerns, see section VIII). This section also notes where additional information must be provided under § 312.22(b) when an IND is for a botanical product that has been marketed in one or more foreign countries but not the United States.

A. **Description of Product and Documentation of Human Use**
1. Description of Botanicals Used (§ 312.23(a)(3)(i))

The following information should be provided for each of the botanical raw materials used as ingredients in a botanical drug product:

- Common or usual names of the plant, alga, or macroscopic fungus
- Synonyms (e.g., Latin, Greek, English, Spanish, Chinese)
- Name of variety, species, genus, and family, including the name of the botanist who first described the species or variety, if known
- Chemical class of the active constituent (the chemical constituent that is responsible for the claimed pharmacological activity or therapeutic effect) or characteristic marker (a chemical constituent used for identification and/or quality control purposes), if known

2. History of Use (§ 312.23(a)(3)(ii),(a)(9))

The sponsor should include information found in historical sources (e.g., books of medical practice in Ayurveda, traditional Chinese medicine, Unani, Sida) and scientific literature about the prior human use of the botanical product, and each of its ingredients, in traditional foods and drugs. Any literature submitted must be provided in English (and in its original language, if other than English) (§ 312.23(c)).

3. Current Marketed Use (§ 312.23(a)(3)(ii), (a)(9))

The sponsor must include information about the nature and extent of the current worldwide use of the botanical product, and each of its ingredients, in foods and drugs, including evidence concerning its marketing experience in the United States and/or foreign countries. For a foreign-marketed botanical product, the sponsor should provide data that verify its safe human use, including proof of the annual sales volume, an estimate of the size of the exposure population, and the rate of adverse effects.

B. Chemistry, Manufacturing, and Controls

Outlined below is the CMC information that we recommend you submit, in meeting the requirements of § 312.23(a)(7), in an IND to support a phase 1 or phase 2 clinical trial on a botanical product that is currently lawfully marketed without any known safety issues in the United States and/or a foreign country. Literature references and relevant official compendia or published standards should be provided whenever possible.

1. Botanical Raw Material (§ 312.23(a)(7)(i))

The information discussed in section VII.A.1 should be provided for all currently lawfully marketed products. It is important for the safe conduct of clinical trials to
ensure the proper identity of botanical raw materials used in the trials. Since there is no history of U.S. experience for botanical raw materials marketed only outside the United States, a certificate of authenticity of the plant and plant parts should be provided for such materials. A trained professional who is competent to determine authenticity should sign this certificate. This information also should be provided, if available, for a botanical raw material marketed in the United States.

2. *Botanical Drug Substance* (§ 312.23(a)(7)(iv)(a))

The general method of preparation (e.g., pulverization, decoction, expression, aqueous extraction, or ethanolic extraction) must be provided under § 312.23(a)(7)(iv)(a). This is especially important where more than one process exists in the literature on which the safety of the botanical drug substance is based.

3. *Botanical Drug Product* (§ 312.23(a)(7)(iv)(b))

A botanical drug product is manufactured from a botanical drug substance by adding one or more excipients, mixing, blending, granulating, tableting, encapsulating, or performing other dosage-form-specific procedures, followed by packaging. When packaged without further processing, a botanical drug substance is considered the drug product. We recommend that the following information be provided for a botanical drug product:

- A qualitative description of the finished product, including the dosage form, route of administration, names of all ingredients (i.e., botanical drug substance and excipients), and a statement that the product is not adulterated with potent, toxic, or addictive botanical substances, synthetic or highly purified drugs, biotechnology-derived drugs, or other naturally derived drugs.

- The composition or quantitative description of the finished product (i.e., the quantity of the botanical drug substance and each excipient, if any) expressed in terms of amount per dosage unit. We recommend that sponsors provide this information in tabular form.

**Example for a single-herb botanical drug product**

<table>
<thead>
<tr>
<th>Component</th>
<th>Amount per tablet</th>
<th>Amount per batch</th>
</tr>
</thead>
<tbody>
<tr>
<td>Senna leaf extract (8:1 powdered aqueous extract)</td>
<td>250 mg</td>
<td>10.0 kg (equivalent to 80.0 kg of dried leaves)</td>
</tr>
<tr>
<td>Excipient 1</td>
<td>100 mg</td>
<td>4.0 kg</td>
</tr>
<tr>
<td>Excipient 2</td>
<td>10 mg</td>
<td>0.4 kg</td>
</tr>
</tbody>
</table>

The amount may also be expressed on the basis of amount of botanical raw material (e.g., weight of dried leaves).
<table>
<thead>
<tr>
<th>Component</th>
<th>Amount per tablet</th>
<th>Amount per batch</th>
</tr>
</thead>
<tbody>
<tr>
<td>Senna</td>
<td>250 mg (equivalent to 2000 mg dried leaves)</td>
<td>10.0 kg (equivalent to 80.0 kg of dried leaves)</td>
</tr>
<tr>
<td>Excipient 1</td>
<td>100 mg</td>
<td>4.0 kg</td>
</tr>
<tr>
<td>Excipient 2</td>
<td>10 mg</td>
<td>0.4 kg</td>
</tr>
</tbody>
</table>

**Example for a multi-herb botanical drug product:**

<table>
<thead>
<tr>
<th>Component</th>
<th>Amount per tablet</th>
<th>Amount per batch</th>
</tr>
</thead>
<tbody>
<tr>
<td>A 5:1 powdered, aqueous extract from 1:1 mixture of <em>Forsythia suspensa</em></td>
<td>600 mg</td>
<td>24 kg</td>
</tr>
<tr>
<td>Vahl. flowers and <em>Lonicera japonica</em> Thunb. fruits</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Excipient 1</td>
<td>100 mg</td>
<td>4.0 kg</td>
</tr>
<tr>
<td>Excipient 2</td>
<td>10 mg</td>
<td>0.4 kg</td>
</tr>
</tbody>
</table>

- The manufacturer’s certificate of analysis for the study product or, if none is available, authorization to allow FDA to cross-reference the manufacturer’s previous submission for the relevant CMC information. If this information is unavailable for a foreign-marketed product, the sponsor should perform quality testing on the product according to the recommendations listed under section VIII.B.3. In addition to those tests, heavy metal analysis, and an animal safety test (see below), if applicable, should be performed. The test methods and results should be provided in the IND. The study product should be from a single source and, where feasible, from a single batch. A product sample from the batch to be used in the clinical study should be retained for possible future testing by FDA and/or the sponsor.

4. **Animal Safety Test (§ 312.23(a)(8))**

An animal safety test (different from the rabbit pyrogen test, USP <151>) is an acute animal toxicity test applied only to injectable drug products. We recommend that this test be performed for crude extracts from natural sources, especially when the raw material, process, and final product cannot be fully characterized and controlled.

5. **Placebo (§ 312.23(a)(7)(iv)(c))**

The components of any placebo used must be described.

6. **Labeling (§ 312.23(a)(7)(iv)(d))**

The following labeling information must be provided:
Contains Nonbinding Recommendations

- A copy of the container label and the immediate outer carton label of the marketed product to be used in the clinical study.

- A mock or printed representation of the proposed container label that will be provided to the investigators in the proposed clinical study. It should contain the following information: protocol number; patient number; sponsor’s name; product name or code number; strength and/or potency; recommended storage conditions; lot number; and (as required under § 312.6) the statement, “Caution: New drug -- Limited by Federal law to investigational use.” In a placebo-controlled clinical trial, both the study drug and the placebo should be properly labeled to protect the integrity of the blinded study.

7. Environmental Assessment or Claim of Categorical Exclusion
   (§ 312.23(a)(7)(iv)(e))

A claim for categorical exclusion from the requirement for preparation of an environmental assessment (EA) ordinarily can be made for an IND (21 CFR 25.31(e)).

C. Pharmacology/Toxicology Information

1. All Marketed Botanical Products

Under § 312.23(a)(8), previous human experience and available animal toxicity data concerning the clinical formulation and the individual botanical ingredients within the formulation must be provided to support initial clinical trials (phase 1 and phase 2) of a botanical drug product for the proposed use. As noted in section VI.A, initial studies for botanical products with no known safety concerns and that have been marketed in the United States as dietary supplements may generally be conducted without further pharmacologic/toxicologic testing. Nevertheless, available information should be provided. A database search should be conducted, when feasible, to identify information relevant to the safety and effectiveness of the following:

- the final formulation of the intended commercial botanical drug product
- the individual botanical ingredients
- the known chemical constituents of the botanical ingredients.

Under § 312.23(a)(8)(ii), an integrated summary of available data from medical and toxicological databases (e.g., Medline, Toxline, TOMES, RTEC) must be submitted for review. Using the information gathered from this literature, the sponsor should address, as appropriate for the proposed study, the following issues concerning the botanical drug product:

- general toxicity
- target organs or systems of toxicity
Contains Nonbinding Recommendations

• teratogenic, carcinogenic, or mutagenic potential of any botanical ingredient in the product
• relationship of dosage and duration to toxic responses
• pharmacological activity.

2. Foreign-Marketed Botanical Products

For the reasons discussed in section VI, additional information must be provided in accordance with § 312.22(b) for a botanical product that has been previously marketed but not in the United States. In addition to the information listed above, the sponsor should provide data that support safe human use and should include the annual sales volume, an estimate of the size of the exposure population, and available data on the rate of adverse effects. The nature of nonclinical pharmacology/toxicology information needed before a sponsor conducts an initial clinical study will be determined on a case-by-case basis, depending on the indications, proposed dose, duration and size of study, and available data supporting safe human experience.

D. Bioavailability

Pharmacokinetic and pharmacodynamic information is helpful in the design and interpretation of clinical studies. Since botanical products often consist of more than one chemical constituent and the active constituents are often unknown, standard pharmacokinetic measurements to demonstrate systemic exposure to a product in animals and/or humans may be difficult to obtain. However, when feasible, sponsors are encouraged to monitor the blood levels of known active constituents, representative markers, or major chemical constituents in a botanical drug product (see section IX.D).

E. Clinical Considerations

The initial clinical trial for a botanical product currently marketed under the DSHEA will ordinarily be a well-controlled study capable of demonstrating effectiveness. Because the product is marketed and the dose that is thought to be appropriate and well tolerated is known, there should be little need for pilot or typical phase 1 studies, and uncontrolled observations are unlikely to be useful. Sponsors are therefore strongly encouraged to initiate more definitive trials early in the development program to determine whether a botanical product has efficacy for one or more claimed indications. Safety data should be collected during the trials. If there is doubt about the best dose of the product tested, a randomized, parallel, fixed-dose, dose-response study may be particularly useful as an initial trial.

Regarding the safety of the drug, a botanical preparation lawfully marketed in the United States will generally be considered acceptable for at least short-term (e.g., up to several months) use in clinical trials. For foreign-marketed botanical products, safety considerations will be based on available CMC, pharmacology, and toxicology information, as well as indications, proposed doses, duration and size of the study, and available data supporting safe human use.
VIII. INDS FOR PHASE 1 AND PHASE 2 CLINICAL STUDIES FOR NONMARKETED BOTANICAL PRODUCTS AND PRODUCTS WITH KNOWN SAFETY CONCERNS

This section discusses the type of information that we recommend be provided in meeting the requirements for INDs for initial trials of botanicals that (1) have not previously been lawfully marketed in the United States or elsewhere or (2) that have been marketed and have known safety issues.

A. Description of Product and Documentation of Human Use

In addition to the information outlined in section VII.A.1-2, the following should be provided in accordance with the listed subsections of § 312.23 for each raw material contained in a botanical product not lawfully marketed in either the United States or other countries:

1. Description of Botanicals Used (§ 312.23(a)(3)(i))
   - Morphological and anatomical description (including gender, if applicable) and a photograph of the plant or plant part, alga, or macroscopic fungus used
   - Natural habitat and geographical distribution of the plant, alga, or macroscopic fungus
   - Current sources of the plant, alga, or macroscopic fungus, including its geographical location and whether it is cultivated or harvested from the wild
   - A statement indicating whether the species is any of the following:
     - Determined to be endangered or threatened under the Endangered Species Act or the Convention on International Trade in Endangered Species of Wild Fauna and Flora;
     - Entitled to special protection under some other Federal law or international treaty to which the United States is a party;
     - The critical habitat of a species that has been determined to be endangered or threatened

2. History of Use (If Any) (§ 312.23(a)(3)(ii), (a)(9))
   - Method of preparation, processing, and formulation
Contains Nonbinding Recommendations

- Routes, schedules, and doses of administration
- Medical claims
- Contraindications and adverse events associated with use in humans and animals
- Traditional geographical areas and populations in which such use occurred
- A description of the similarities and/or differences between the traditional preparation and the proposed clinical formulation

3. Current Investigational Use (If Any) (§ 312.23(a)(3)(ii), (a)(9))

- Proposed therapeutic claim and dose regimen (mg/kg/dose and dose/day)
- All available information in the literature that addresses the proposed therapeutic claim, including both positive and negative studies

B. Chemistry, Manufacturing, and Controls

Outlined below is the CMC information that should be submitted, in meeting the requirements of § 312.23(a)(7), in an IND to support a phase 1 or phase 2 clinical trial using a botanical product that is not currently lawfully marketed in the United States or a foreign country, or for which there are known safety issues.

1. Botanical Raw Material (§ 312.23(a)(7)(i))

A botanical drug substance can be derived from one or more botanical raw materials. The following recommendations apply to each individual botanical raw material used.

The botanical raw material should be described as outlined in sections VII.A.1 and VIII.A.1. If the botanical raw material has no documented history of use, the IND sponsor should so indicate. The following information should be provided:

- Identification by trained personnel of the plant, plant parts, alga, or macroscopic fungus used, including organoleptic, macroscopic, and microscopic examination. The identification should be done against a voucher specimen (reference specimen). If more than one variety of a given species is used, each should be specified. A sample of the plant, plant parts, or other botanical materials should be retained and stored under appropriate conditions by the raw material supplier and botanical drug substance manufacturer for each batch. These samples will be used for verification of identity, if needed.

- A certificate of authenticity
A list of all grower(s) and/or supplier(s) (including names and addresses). The following items should be provided for each grower/supplier, if available:

- Harvest location
- Growth conditions
- Stage of plant growth at harvest
- Harvest time
- Collection, washing, drying, and preservation procedures
- Handling, transportation, and storage conditions

2. Botanical Drug Substance (§ 312.23(a)(7)(iv)(a))

The following information should be provided for all botanical drug substances, regardless of whether they are prepared from one or more botanical raw materials:

- A qualitative description of the drug substance, including the name, appearance, physical and chemical properties, active constituent (if known), biological activity (if known), and clinical indication (if known) of each botanical raw material. If the active constituent, biological activity, and/or clinical indication is unknown, the IND sponsor should clearly so state. In the case of a multi-herb substance, the sponsor should state whether the drug substance is prepared by combining individually processed botanical drug substances or by processing combined botanical raw materials.

- The quantitative description (strength) of the drug substance. Historically, the strength of a botanical drug substance is expressed simply as the absolute dry weight of the processed substance. The batch size and the yield of the process, relative to the botanical raw material, also should be indicated. Furthermore, where the active constituents or other chemical markers are known and measurable, the amount in which they are present in the botanical drug substance should be declared. For a multi-herb substance, its composition should be expressed in terms of the relative ratio of the individually processed botanical drug substances or of the botanical raw materials before processing, whichever is appropriate.

- The name and address of the drug substance manufacturer (processor).

- A description of the manufacturing process for the botanical drug substance. The description should include the quantity of botanical raw material, solvents, extraction and/or drying, and yield. The yield of the process, expressed as the amount of the original botanical raw material relative to the amount of the extract, also should be
indicated. If more than one botanical raw material is introduced to produce a multi-herb substance, the quantity of each raw material and the sequence of addition, mixing, grinding, and/or extraction should be provided. If a multi-herb substance is prepared by combining two or more individually processed botanical drug substances, the process leading to each botanical drug substance should be described separately.

- The quality control tests performed on each batch of the drug substance, the analytical procedures used, and the available test results. These tests should include, but need not be limited to, the following attributes:
  
  - Appearance
  
  - Chemical identification by spectroscopic and/or chromatographic fingerprints. Examples of spectroscopic methods include ultraviolet, infrared, Fourier transformed infrared, and mass spectroscopy. Examples of chromatographic methods include high performance liquid chromatography (HPLC), HPLC with diode array detection, thin layer chromatography (TLC), 2-dimensional-TLC, and gas chromatography.

  - Chemical assay (i.e., assay) for active constituents or characteristic markers. If several botanical raw materials are combined to produce a multi-herb substance and a quantitative determination of each individual active constituent or marker is infeasible, a joint determination can be made for several active constituents or markers. When multiple active constituents or markers are known, they should be chemically characterized and their relative amounts should be defined.

  - Biological assay (when the active chemical constituent(s) are not known or quantifiable), if available. If the botanical drug substance is considered potent (i.e., highly active), toxic, addictive, or has abuse potential (e.g., ephedra or marijuana), an assay for biological activity and/or a chemical assay for the active constituent(s) should be performed.

  - Strength by dry weight (equivalent to botanical raw material)

  - Heavy metals

  - Microbial limits

  - Animal safety test, if applicable

- A description of the container/closure in which the botanical drug substance is to be stored and/or shipped.

- Available stability data on the drug substance. The sponsor should develop stability-indicating analytical methods and conduct stability studies as the IND progresses.
The container label, which should reflect the qualitative and quantitative description of the botanical drug substance, as discussed above, and recommended storage conditions. Examples of labeling for single-herb and multi-herb substances are shown below:

**Single-herb substance:**

- Expressed in terms of yield:
  - Senna, 10 kg, equivalent to 80 kg of dried leaves
  - Senna, 10 kg, 8:1 (w/w) powdered extract of dried leaves

- Expressed in terms of active constituents:
  - Senna, 10 kg extract, containing 2 kg of hydroxyanthracene glycosides (sennosides), calculated as sennoside B

- Expressed in terms of chemical markers:
  - Valerian, 10 kg extract, containing 0.1 kg valerinic acid

**Multi-herb substance:**

- Prepared by combining individually processed botanical drug substances:
  - *Lonicera japonica* Thunb. and *Forsythia suspensa* Vahl., 6 kg, containing 3 kg of *Lonicera japonica* Thunb. 4:1 solid extract and 3 kg of *Forsythia suspensa* Vahl. 6:1 solid extract

- Prepared by processing combined botanical raw materials:
  - *Lonicera japonica* Thunb. and *Forsythia suspensa* Vahl., 6 kg, a 5:1 powdered extract prepared from 15 kg of *Lonicera japonica* Thunb. and 15 kg of *Forsythia suspensa* Vahl

3. **Botanical Drug Product (§ 312.23(a)(7)(iv)(b))**

The following information should be provided:

- A qualitative description of the finished product (see section VII.B.3.)

- The composition, or quantitative description, of the finished product (i.e., the name and quantity of the botanical drug substance and of each excipient (if any), expressed in terms of amount per dosage unit and amount per batch). This information should be provided in tabular form. A quantitative description of the drug substance should be provided as described in section VIII.B.2.
**Example:**

<table>
<thead>
<tr>
<th>Component</th>
<th>Amount per tablet</th>
<th>Amount per batch</th>
</tr>
</thead>
<tbody>
<tr>
<td>Senna</td>
<td>250 mg (equivalent to 2000 mg dried leaves)</td>
<td>10.0 kg (equivalent to 80.0 kg of dried leaves)</td>
</tr>
<tr>
<td>Excipient 1</td>
<td>100 mg</td>
<td>4.0 kg</td>
</tr>
<tr>
<td>Excipient 2</td>
<td>10 mg</td>
<td>0.4 kg</td>
</tr>
</tbody>
</table>

- The name and address of the manufacturer of the finished drug product

- A description of the manufacturing process. (If the botanical drug substance is filled and packaged directly as the finished product without the addition of excipients and further processing, this item and items listed in the immediately preceding two bullets will not apply.)

- A list of the quality control tests performed on each batch of the drug product, and the analytical procedures used and the available test results. These tests should include, but need not be limited to, the following attributes:
  - Appearance
  - Chemical identification by spectroscopic and/or chromatographic fingerprints
  - Assay for active constituents or characteristic markers, if available. If several botanical raw materials are combined to produce a multi-herb substance and a quantitative determination of each individual active constituent or marker is infeasible, a joint determination can be carried out for several active constituents or markers. When multiple active constituents or markers are known, they should be chemically characterized and their relative amounts should be defined.
  - Biological assay (when the active chemical constituent(s) are not known or quantifiable), if available. If the botanical drug substance is considered potent (i.e., highly active), toxic, addictive, or has abuse potential (e.g., ephedra or marijuana), an assay for biological activity and/or a chemical assay for the active constituent(s) should be performed.
  - Strength by dry weight (of drug substance)
  - Microbial limits
  - Other attributes specific to the dosage form of interest (e.g., dissolution for solid oral dosage forms, sterility and nonpyrogenicity for parenterals, animal safety test for parenterals, when appropriate).
Contains Nonbinding Recommendations

- A description of the container/closure in which the drug product is to be packaged
- Available stability data on the drug product. The sponsor should develop stability-indicating analytical methods (using markers when feasible) and conduct stability studies as the IND progresses.

4. Placebo (see section VII.B.5)

5. Labeling (see section VII.B.6)

Additionally, a quantitative description of the drug substance per dosage unit (as described in section VIII.B.2.h and 3.b) should be provided. An example of a quantitative description for a multi-herb botanical drug product is shown below:

BRAND X. 100 tablets. Each 1-gram tablet contains:
300 mg of *Lonicera japonica* Thunb.4:1 solid extract and
300 mg of *Forsythia suspensa* Vahl. 6:1 solid extract

6. Environmental Assessment or Claim of Categorical Exclusion

A claim for categorical exclusion from the requirement for preparation of an EA ordinarily can be made for an IND (§ 25.31(e)). However, FDA will require at least an EA for any specific action that ordinarily would be excluded if extraordinary circumstances indicate that the specific proposed action may significantly affect the quality of the human environment (21 CFR 25.21; 40 CFR 1508.4). CDER will evaluate INDs on a case-by-case basis when the drug or biological product is derived from wild plants or animals to determine whether the extraordinary circumstance provision in § 25.21 is applicable. FDA encourages early consultation with the Agency on environment-related aspects of a requested action, especially one that involves harvesting a wild species, to ensure that planning and decisions reflect environmental values, avoid delays later in the process, and avoid potential conflicts (§ 25.10(b) and (c)). For additional information, see 21 CFR part 25, 40 CFR parts 1500-08, and the CDER/CBER guidance for industry on *Environmental Assessment of Human Drug and Biologics Applications* (July 1998). An environmental assessment or a claim for categorical exclusion must be provided as required under § 25.15(a).

C. Nonclinical Safety Assessment

1. Traditional Preparations

Nonclinical pharmacology and toxicology studies are particularly important in establishing the safety of a new botanical drug for which there is no current marketing experience. The information is used for assessing the botanical drug's risk-to-benefit ratio, guiding early clinical studies, and predicting potential toxicity.

Because of their extensive use in humans, there may be sufficient information on
A traditional herbal preparation, which may have evolved over time, generally has the following characteristics:

- It meets official compendia or other published standards in terms of the botanical identity and plant part used for each botanical raw material.
- In the case of a multi-herb substance, it is composed of the same formulation as a historical formula, with the amount of each botanical ingredient falling within the range of traditional usage.
- It is prepared by the same processing methodology as traditionally used.
- It is used in the traditional manner in terms of therapeutic indication, route and schedule of administration, and quantities or doses.

For initial clinical studies on a botanical drug product that is not currently lawfully marketed in the United States or elsewhere but is prepared, processed, and used by humans according to an established methodology, sufficient information might be available to support the studies without standard nonclinical testing. In general, the considerations listed under section VII.C are applicable. When the initial clinical study for such a drug shows promising results and further clinical development of the drug is intended, pharmacology and toxicology studies carried out prior to the later phases of the clinical trials may be needed to support a risk-benefit assessment and to identify potential toxicities not readily detected in clinical studies (see section IX.C below).

2. Others

For a botanical product that is not prepared according to a traditional methodology, the extent of variation from the traditional formulation, preparation, or processing should be described in full detail. The nature of nonclinical pharmacology/toxicology information needed before conducting an initial clinical study (in addition to that described under section VII.C) will be determined on a case-by-case basis, depending on the indications, extent of safe human experience, and safety concerns about the new formulation, preparation, or processing methodology used.

3. Products with Known Safety Issues

For those botanical drugs for which there are known safety issues, the nature of the nonclinical pharmacology/toxicology information needed will be determined on a case-by-case basis to address those issues (see section VI.A).

D. Bioavailability

Pharmacokinetic and pharmacodynamic information is helpful in the design and
interpretation of clinical studies. As stated in section VII.D, a botanical product’s active constituents may be unknown, and standard pharmacokinetic measurements to demonstrate systemic exposure to a product in animals and/or humans may be infeasible due to the complexity of the botanical drug. However, when feasible, a sponsor is encouraged to monitor the blood levels of known active constituents, representative markers, or other major chemical constituents in a botanical drug product. Because there is less human use experience with botanical products that have never been lawfully marketed than with those that have been, a sponsor of a drug that has not been lawfully marketed should consult FDA’s guidances *Drug Metabolism/Drug Interaction Studies in the Drug Development Process: Studies In Vitro* (April 1997) and *In Vivo Drug Metabolism/Drug Interaction Studies—Design, Data Analysis, and Recommendations for Dosing and Labeling* (November 1999) to assess potential drug-drug interaction when a clinical study includes co-administration with another drug (see section IX.D).

For a botanical product that is prepared according to traditional methodology, the nature of clinical pharmacology information needed should be determined on a case-by-case basis, depending on the indications, extent of human experience, target patient population, and projected length of clinical use.

E. Clinical Considerations

In general, initial clinical investigations of nonmarketed botanical preparations should be similar to those of marketed products (see section VII.E). Because of the lack of current marketing experience, however, greater concerns could exist about toxicity. Therefore, FDA will seek greater assurance of the safety of the product for initial clinical trials in the United States. Such assurance may be provided in the form of additional chemical analysis and/or additional toxicology data. It may also be helpful to provide documentation of the product’s previous safe human use by referencing literature and/or pharmacopoeias.

IX. INDS FOR PHASE 3 CLINICAL STUDIES OF ALL BOTANICAL PRODUCTS

When conducting expanded (i.e., phase 3) clinical studies on a botanical drug product, an IND sponsor is expected to provide more detailed information on CMC and nonclinical safety than when conducting a phase 1 or phase 2 study (§ 312.22(b), 312.23(a)(7)(i) and (8)). The better definition of the product will ensure an ability to apply data from trials to a well-controlled, reproducible substance. The additional toxicology data are needed to support wider use. This additional information should be provided regardless of whether the product is currently lawfully marketed in the United States or elsewhere as a dietary supplement.

For phase 3 clinical studies of a botanical product, the following information should be provided in meeting the requirements of § 312.23:

A. Description of Product and Documentation of Human Experience
See sections VII.A and VIII.A for guidance on how to describe the botanical product and human experience with it.

**B. Chemistry, Manufacturing, and Controls**

To support phase 3 clinical trials of a botanical product, regardless of its marketing experience in the United States or other countries, the following CMC information should be provided in accordance with § 312.23(a)(7) unless already submitted in the IND for phase 1/phase 2 studies on the product:

1. **Expanded Clinical Studies**

   a. Botanical raw material

      - A description of the botanical raw material as outlined in sections VII.A.1 and VIII.A.1. If the botanical has no documented history of use, this should be indicated. Proper identification by trained personnel of the plant, plant parts, alga, or macroscopic fungus used, including organoleptic, macroscopic, and microscopic examination, should be provided. The identification should be done against a voucher specimen (reference specimen). If more than one variety or source of a given species is used, they should be blended in a fixed proportion in a consistent manner. A sample of the plant, plant parts, or other botanical materials should be retained for every batch by the raw material supplier and drug substance manufacturer, and stored under appropriate conditions for future verification of identity. In addition, a certificate of authenticity and information on the grower and/or supplier, growing conditions (including pesticides used), harvest location, harvest time (including stage of plant growth at harvest), handling, and shipping should be provided.

      - A spectroscopic and/or chromatographic fingerprint of each botanical raw material and the chemical identity of the active constituents or characteristic markers in the botanical raw material

      - The name and address of the botanical raw material manufacturer (processor)

      - A description of the preparation of the botanical raw material, including collection, washing, drying, preservation, and/or detoxification and preservation procedures. Equipment and quantity used, temperature employed, processing time, in-process controls, and yield should be specified.

      - The quality control tests and analytical procedures applied by the botanical raw material supplier, and the proposed acceptance criteria. These tests should include, but need not be limited to, the following attributes:

        – Botanical identification

        – Chemical identification by spectroscopic and/or chromatographic fingerprint

        – Chemical identification for active constituents or characteristic markers if
active constituents are not known

- Assay for active constituents or characteristic markers if active constituents are not known
- Biological assay (when the active chemical constituents are not known or quantifiable), if available
- Heavy metals
- Microbial limits
- Residual pesticides, including parent pesticides and their major toxic metabolites
- Adventitious toxins (e.g., aflatoxins)
- Foreign materials and adulterants

In some cases (e.g., when the botanical raw material undergoes further processing to prepare the botanical drug substance), reduced testing may be appropriate for certain assays (e.g., heavy metals), if these assays are routinely performed on the botanical drug substance. If some of these tests cannot be performed by the raw material supplier, the botanical drug substance manufacturer should perform the tests upon receipt of the botanical raw material.

- A photocopy of the voucher specimen (reference specimen) of the botanical raw material used in identification, fingerprinting, and other comparative and noncomparative tests
- A certificate of analysis for representative batch(es) of the botanical raw material
- A description of the storage conditions, including the container/closure system and temperature

b. Botanical drug substance (§ 312.23(a)(7)(iv)(a))

- A qualitative and quantitative description of the drug substance and the name and address of the manufacturer (see section VIII.B.2).

- A chemical identification for the active constituents or characteristic markers in the drug substance, if possible. If the chemical identity is unknown, a representative spectroscopic and/or chromatographic fingerprint may suffice.

- Appropriate acceptance specifications (tests, test procedures, and acceptance criteria) for the botanical raw material, similar to the list of quality control specifications in section IX.B.1.a, established by the botanical drug substance manufacturer. Upon receipt of each batch of the raw material and its certificate of analysis, the manufacturer should, at a minimum, conduct an identification test and assay.

- A description of the manufacturing process for the botanical drug substance. The description should include the quantity of botanical raw material,
Contains Nonbinding Recommendations

equipment, solvents, temperature/time for mixing, grinding, extraction and/or drying, yield, and in-process controls. The yield of the process, expressed as the amount of the original botanical raw material relative to the amount of the extract, also should be indicated. If more than one botanical raw material is introduced to produce a multi-herb substance, the quantity of each raw material and the sequence of addition, mixing, grinding, and/or extraction should be provided. If a multi-herb substance is prepared by combining two or more individually processed botanical drug substances, the process leading to each botanical drug substance should be described separately.

• The quality control tests performed on each batch of drug substance, the analytical procedures used, and the proposed acceptance criteria. These tests should include, but need not be limited to, the following attributes:

  – Appearance
  – Chemical identification by spectroscopic and/or chromatographic fingerprints
  – Chemical identification for the active constituents or, if unknown, the characteristic markers
  – Chemical assay for the active constituents, or the characteristic markers if the active constituents cannot be determined. If several botanical raw materials are combined to produce a multi-herb substance and a quantitative determination of each individual active constituent or marker is infeasible, a joint determination can be made for several active constituents or markers. When multiple active constituents or markers are known, they should be chemically characterized and their relative amounts should be defined.
  – Biological assay (when the active chemical constituents are not known or quantifiable), if available. If the botanical drug substance is considered potent (i.e., highly active), toxic, or addictive, or has abuse potential (e.g., ephedra or marijuana), an assay for biological activity and/or a chemical assay for the active constituent(s) should be performed.
  – Strength by dry weight
  – Residue on ignition
  – Water content
  – Residual solvents
  – Heavy metals
  – Microbial limits
  – Animal safety test, if applicable
  – Residual pesticides
  – Radioisotope contaminants, if applicable
Contains Nonbinding Recommendations

- Adventitious toxins (e.g., aflatoxins)
- Endogenous toxins (e.g., pyrrolizidine alkaloids)
- Other attributes specific to the botanical raw materials from which the drug substance is derived

- Validation reports of all analytical procedures, where appropriate
- A description of the batch of botanical drug substance designated as the reference standard for use in fingerprinting and other comparative tests
- Batch analysis (i.e., test results for representative batches)
- A description of the container and closure used to package the botanical drug substance
- Sufficient stability data on the drug substance to support its safe use during clinical studies; stability-indicating analytical methods
- Information on the container label as described in section VIII.B.2

c. Botanical drug product (§ 312.23(a)(7)(iv)(b))

- A qualitative description and the composition of the dosage form and the name and address of the manufacturer (see section VIII.B.3)
- Appropriate acceptance specifications established by the botanical drug product manufacturer for the botanical drug substance, similar to the quality control tests in section IX.B.1.b. Upon receipt of each batch of the drug substance and its certificate of analysis, the manufacturer should, at a minimum, conduct an identification test and assay.

- A description of the manufacturing process, without the actual batch record. The description should include weighing, mixing, blending, sieving, in-process controls, and other processes, as appropriate.

- The quality control tests performed on each batch of drug product, the analytical procedures used, and the proposed acceptance criteria. These tests should include, but need not be limited to, the following attributes:
  - Appearance
  - Chemical identification by spectroscopic and/or chromatographic fingerprints
  - Chemical identification for the active constituents or, if unknown, the characteristic markers
  - Chemical assay for active constituents or, if unknown, the characteristic markers. If several botanical raw materials are combined to produce a multi-herb substance and a quantitative determination of each individual active constituent or marker is infeasible, a joint determination can be
made for several active constituents or markers. When multiple active constituents or markers are known, they should be chemically characterized and their relative amounts should be defined.

– Biological assay (when the active chemical constituent(s) are not known or quantifiable), if available. If the botanical drug substance is considered potent (i.e., highly active), toxic, addictive, or has abuse potential (e.g., ephedra or marijuana), an assay for biological activity and/or a chemical assay for the active constituent(s) should be performed.

– Strength by dry weight (of drug substance)
– Residual solvents
– Microbial limits
– Adventitious toxins (e.g., aflatoxins)
– Other attributes specific to the dosage form of interest (e.g., dissolution for solid oral dosage forms, sterility for parenterals, animal safety test for parenterals, when appropriate).

• Validation reports of all analytical procedures, where appropriate
• Batch analysis (i.e., test results for representative batches)
• A description of the container and closure used to package the finished product
• Sufficient stability data on the drug substance to support its safe use during clinical studies. Stability-indicating analytical methods should be established.

d. Placebo (see section VII.B.5)

e. Labeling (see sections VII.B.6 for investigational labels and VIII.B.5 for quantitative description)

f. An EA or a claim of categorical exclusion (see section VIII.B.7)

2. *End-of-Phase 3 Clinical Studies and Pre-NDA Considerations*

Sponsors must continue to characterize the drug substance and the drug product throughout the entire clinical development program ((§ 312.23(a)(7)). By the end of the phase 3 clinical trial, as the sponsor prepares to submit an NDA, the following objectives should be reached:

• Adequate controls for botanical raw materials should be established.

• The manufacturing processes of the drug substance and the drug product should be finalized and validated, and in-process controls should be established. An executed
Batch-to-batch consistency should be demonstrated for the botanical drug substance and drug product based on results from all chemical, physical, and biological tests on all relevant batches. To achieve this goal, multiple fingerprints, using a combination of analytical methods with different separation principles and test methods, can be useful. All chemical constituents detected by spectroscopic and/or chromatographic fingerprinting should be qualitatively and quantitatively comparable from batch to batch.

Appropriate specifications (i.e., tests, analytical procedures, and acceptance criteria), including identification and assay for active constituents, identification and assay for characteristic markers, and/or biological assay (when the active chemical constituent(s) are not known or quantifiable), should be established to control the quality of the drug substance and product. Both the active constituents and the biological assay should be clinically relevant. If the identity of the active constituents is not known or a suitable assay cannot be developed, the characteristic markers should be demonstrated to be clinically relevant by direct or indirect correlation to the clinical outcome.

Analytical procedures should be properly validated. Analytical procedures used for fingerprinting should be verified for specificity and should be capable of detecting as many chemical classes (e.g., proteins, carbohydrates, fatty acids, small organic compounds) present and as many individual chemical constituents as possible. Additionally, when multiple fingerprints are used, the analytical procedures in combination should be able to demonstrate the mass balance in the test sample, on the basis of the different classes of chemicals and, if appropriate, among the individual constituents detected within a chemical class.

A suitable voucher specimen (reference specimen) for each of the botanical raw materials should be established, along with a reference standard for the drug substance and drug product.

Stability-indicating analytical methods should be developed to monitor the stability of the drug substance and drug product. The stability of a botanical drug substance or product generally should not be based entirely on the assay of the active constituents, assay of the characteristic markers, or biological assay, because degradants formed during storage from other chemical constituents in the botanical drug substance or product should also be controlled. An analytical method capable of detecting these degradants (such as a spectroscopic and/or chromatographic fingerprint) should be established through exploratory studies by subjecting the drug substance and drug product to stress conditions.

A biological assay, when used for characterization and quality control of a drug substance and drug product, should be properly validated. The ICH Guideline Q6B Specifications: Test Procedures and Acceptance Criteria for
Biotechnological/Biological Products (August 1999) and the USP XXV Biological Tests <111>: Design and Analysis of Biological Assays provide useful information on biological assays. Performing a biological assay calls for the use of a suitable reference standard and, frequently, positive and negative controls. Because biological assays are usually more variable than chemical assays, a relatively higher coefficient of variation is generally justifiable.

- A comparison of the similarities and/or differences in CMC among the nonclinical, clinical, and intended commercial products should be made regarding raw materials, drug substance, and drug product.

- The manufacturing, processing, and controls (receipt, identification, storage, handling, sampling, testing, and approval or rejection of components, drug products, and container closures) for botanical drug products must be in conformance with CGMP as set forth in 21 CFR parts 210 and 211. In addition, the manufacturing, processing, and controls for the botanical drug substance (starting from the botanical raw material) should be in conformance with CGMP because these elements can affect the quality, safety, and efficacy of the drug product. A satisfactory inspection is necessary for NDA approval.

- A sponsor should be preparing the submission in the NDA of either an EA or a claim for categorical exclusion from the requirement for preparation of an EA (§ 25.15(a)). Classes of NDAs that are categorically excluded and, therefore, ordinarily do not require preparation of an EA are listed in § 25.31. However, FDA will require at least an EA for any specific action that ordinarily would be excluded if extraordinary circumstances indicate that the specific proposed action may significantly affect the quality of the human environment (§ 25.21; 40 CFR 1508.4). The Agency regards the submission of an NDA for a drug derived from plants taken from the wild as an extraordinary circumstance requiring the submission of an EA. See section VIII.B.6 for additional information.

Applicants are encouraged to discuss with the review division any CMC issues regarding a botanical drug prior to the preparation and submission of an NDA.

C. Nonclinical Safety Assessment

To support safety for expanded clinical studies or to support marketing approval of a botanical drug product, toxicity data from standard toxicology studies in animals may be needed in accordance with § 312.23(a)(8). A botanical product submitted for marketing approval as a drug will be treated like any other new drug under development. Safety data from previous clinical trials conducted in foreign countries will be considered in determining the need for nonclinical studies. However, previous human experience may be insufficient to demonstrate the safety of a botanical drug product, especially when it is indicated for chronic therapy. Systematic toxicological evaluations could be needed to supplement available knowledge on the general toxicity, teratogenicity, mutagenicity, and carcinogenicity of the final botanical drug product. Depending on the indication
(e.g., target patient population, disease to be treated), route of administration, and duration of recommended drug exposure, the timing of these animal studies in relation to concurrent clinical trials and other requirements for nonclinical animal studies can vary.

In general, animal studies should, as much as possible, be conducted using the same drug substance prepared and processed in the same manner as the drug substance used in clinical trials.

The following are points to consider in preparing a nonclinical pharmacology/toxicology development plan for a botanical drug product that is intended to be used in large-scale human trials or to support an NDA. If questions arise during any stage of the clinical development of a botanical drug, sponsors are encouraged to consult the appropriate review division in CDER.

1. **Repeat-Dose General Toxicity Studies**

The primary objective of long-term, repeat-dose toxicity studies in animals is to identify the organs and/or systems that are the targets of the drug’s toxicity and the threshold doses for producing toxic effects. The studies provide information valuable for designing long-term clinical studies at safe doses, with appropriate monitoring for predicted adverse reactions. Existing literature on the animal toxicity of a botanical drug is often limited to single-dose (acute) studies. These studies would be inadequate to support long-term use.

To support expanded clinical trials, repeat-dose toxicity of a botanical drug should usually be evaluated in two mammalian species (one of which is a nonrodent) by employing sufficiently high doses to produce a toxic effect or by using a maximum feasible dose. If possible, the drug should be tested using the same route of administration as proposed for clinical use. Animal studies should be of a duration at least equal to that of the clinical trial (usually a minimum of 2 weeks). Routinely, general animal toxicity studies need not exceed 6 months of testing in a rodent species and 9 months of testing in a nonrodent species. For additional information on the timing of animal toxicity studies in relation to clinical trials, see the ICH guidance *M3 Nonclinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals* (November 1997).

2. **Nonclinical Pharmacokinetic/Toxicokinetic Studies**

In the development of a new drug that is a single molecular entity, it is often useful to compare pharmacokinetics in animals and humans and to relate exposure levels to toxicities in both animals and humans. Because botanical drugs usually consist of more than one chemical constituent, standard pharmacokinetic measurements to substantiate the systemic exposure of a botanical drug product in animals may be technically infeasible. However, monitoring representative chemical constituents in a botanical drug can provide valuable information regarding systemic exposure. Depending on the complexity of the botanical drug product to be studied, pharmacokinetics could be helpful in the design and interpretation of toxicity studies. For additional information on
toxicokinetic evaluations, see the ICH guidances S3A Toxicokinetics: The Assessment of Systemic Exposure in Toxicity Studies (March 1995) and S3B Pharmacokinetics: Guidance for Repeated Dose Tissue Distribution Studies (March 1995).

3. Reproductive Toxicology

Reproductive toxicology studies, such as those on fertility/reproductive performance, teratology, and prenatal/perinatal development in animals, provide information on the potential of a botanical drug for producing toxicity during the different stages of reproductive and developmental processes. In the absence of documented data on reproductive toxicity in humans or animals, these tests should be conducted prior to expanded clinical trials. For detailed information regarding reproductive toxicology, sponsors should refer to the ICH guidances S5A Detection of Toxicity to Reproduction for Medicinal Products (September 1994) and S5B Detection of Toxicity to Reproduction for Medicinal Products: Addendum on Toxicity to Male Fertility (April 1996).

4. Genotoxicity Studies

We recommend that information on the potential of a botanical drug to produce genetic toxicity be obtained as early as possible, preferably before the initiation of human clinical trials (see ICH M3 Nonclinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals (November 1997)). A complete assessment of genetic toxicity may be needed before expanded clinical trials. A standard battery of tests is defined in the ICH guidances S2A Specific Aspects of Regulatory Genotoxicity Tests for Pharmaceuticals (April 1996) and S2B Genotoxicity: A Standard Battery for Genotoxicity Testing of Pharmaceuticals (November 1997).

If the standard battery of tests chosen indicate that a drug is devoid of genetic toxicity, additional genotoxicity studies may not be needed to comply with § 312.23(a)(8)(ii)(a). If one or more test results are positive, the sponsor may need to carry out additional genotoxicity tests to comply with this provision, in consultation with the appropriate CDER review division.

5. Carcinogenicity Studies

Carcinogenicity studies may be needed to comply with § 312.23(a)(8)(ii)(a) to support marketing approval of a botanical drug, depending on the duration of therapy or any specific cause for concern. The toxicity profile of the botanical drug and the indication and duration of the intended use may influence the need under this regulation for carcinogenicity studies and their timing relative to clinical development (see ICH S1A The Need for Long-Term Rodent Carcinogenicity Studies of Pharmaceuticals (March 1996)). Draft protocols for carcinogenicity studies should be submitted to the appropriate review division and the CDER Carcinogenicity Assessment Committee for review and concurrence prior to the initiation of such studies to ensure the acceptability of dose selection and study design. Study types should be in accordance with the ICH guidance S1B Testing for Carcinogenicity of Pharmaceuticals (February 1998). Doses
used should be chosen according to the principles outlined in the ICH guidances *S1C Dose Selection for Carcinogenicity Studies of Pharmaceuticals* (March 1995) and *S1C(R) Dose Selection for Carcinogenicity Studies of Pharmaceuticals: Addendum on a Limit Dose and Related Notes* (December 1997).

6. **Special Pharmacology/Toxicology Studies**

A general evaluation of the pharmacological effects of a drug on physiological functions (e.g., central nervous system, cardiovascular system) is often performed during new drug development. This evaluation can be accomplished using established in vitro and in vivo assays of broad specificity that screen for the modes and sites of action of the botanical drug. When significant and unique toxicities to certain organs and/or systems are evident, the sponsor should provide further explanation of the mechanism of toxic actions, if appropriate, by performing additional in vitro or in vivo studies.

7. **Regulatory Considerations**

Nonclinical toxicity studies conducted as part of botanical drug development and intended to support safety must be in accordance with regulations governing good laboratory practices under 21 CFR part 58. Both the drug substance and the drug product should be made with batch-to-batch consistency. If changes occur in the drug substance or product during clinical development, bridging toxicity studies might be needed to comply with § 312.23(a)(8)(ii)(a).

**D. Bioavailability and Clinical Pharmacology**

The general requirements for in vivo bioavailability data in an NDA, described in § 320.21, are applicable to botanical drug products. The type of bioavailability study that is appropriate for a specific botanical drug product is based on the following: (1) information on the active constituent, if known; (2) the complexity of the drug substance; and (3) the availability of analytical methods. Because there could be more than one active constituent in a botanical drug or the active constituent may not be identified, it could be difficult or impossible to perform standard in vivo bioavailability and pharmacokinetic studies (e.g., by measuring, as a function of time, the concentration of the active moiety, active ingredients, or active metabolites in whole blood, plasma, serum, or other appropriate biological fluid, or by measuring the excretion of the active moiety or active metabolites in urine). In some cases, it may be possible to measure an acute pharmacological effect as a function of time using an appropriate biological assay method. If this is not possible, the bioavailability of a botanical drug could be based on clinical effects observed in well-controlled clinical trials.

The general criteria for waiver of in vivo bioavailability data in an NDA, described in § 320.22, are applicable to botanical drug products. FDA may, for good cause, waive or defer the in vivo bioavailability study requirement if a waiver or deferral is compatible with the protection of the public health (§ 320.22(e)).
Interactions between botanicals and other commonly used drugs and/or dietary supplements should be investigated. This may include characterization of the metabolic enzymes and/or pathway affected by the drug (see section VIII.D).

Where possible, the effects of impaired clearance (renal or hepatic) on the drug’s pharmacokinetics should be examined. This is easiest when the active substance(s) are known, but even if they are not, knowledge of the major constituents should make it possible to determine the effects of impaired clearance. Dose-response information may indicate the proper level of concern about impaired excretion.

As with synthetic and/or highly purified drugs, pharmaceutical and biopharmaceutics studies for botanical drug products are important for product quality control, batch comparison, and linkage between different strengths. These studies may involve, for example, in vitro dissolution testing, in situ drug absorption testing, in vitro-in vivo correlation studies, or in vitro percutaneous absorption/penetration testing, depending on the indication and formulation of the botanical product.

E. Clinical Considerations

Expanded studies of botanicals have the same purpose as expanded studies of synthetic drugs, including further evaluation of dose-response for favorable and unfavorable effects and evaluation of long-term safety and effectiveness, different populations, different stages/severity of disease, and drug-drug interactions. Many general and therapy-specific guidances are available on CDER's Web page (see title page for URL).
Glossary

The following definitions are intended for use in this guidance only and may not be appropriate in other contexts.

**Active Constituent**: The chemical constituent in a botanical raw material, drug substance, or drug product that is responsible for the intended pharmacological activity or therapeutic effect.

**Botanical; Botanical Product**: A finished, labeled product that contains vegetable matter, which may include plant materials (see below), algae, macroscopic fungi, or combinations of these. Depending in part on its intended use, a botanical product may be a food, drug, medical device, or cosmetic.

**Botanical Drug Product; Botanical Drug**: A botanical product that is intended for use as a drug; a drug product that is prepared from a botanical drug substance. Botanical drug products are available in a variety of dosage forms, such as solutions (e.g., teas), powders, tablets, capsules, elixirs, and topicals.

**Botanical Drug Substance**: A drug substance derived from one or more plants, algae, or macroscopic fungi. It is prepared from botanical raw materials by one or more of the following processes: pulverization, decoction, expression, aqueous extraction, ethanolic extraction, or other similar process. It may be available in a variety of physical forms, such as powder, paste, concentrated liquid, juice, gum, syrup, or oil. A botanical drug substance can be made from one or more botanical raw materials (see Single-Herb and Multi-Herb Botanical Drug Substance or Product). A botanical drug substance does not include a highly purified or chemically modified substance derived from natural sources.

**Botanical Ingredient**: A component of a botanical drug substance or product that originates from a botanical raw material.

**Botanical Raw Material**: Fresh or processed (e.g., cleaned, frozen, dried, or sliced) part of a single species of plant or a fresh or processed alga or macroscopic fungus.

**Cosmetic**: An article intended to be rubbed, poured, sprinkled, or sprayed on, introduced into, or otherwise applied to the human body or any part thereof for cleansing, beautifying, promoting attractiveness, or altering the appearance, or an article intended for use as a component of any such article, except that such term does not include soap (21 U.S.C. 321(i)).

**Dietary Supplement**: The following definition is taken directly from 21 U.S.C. 321(ff).

The term *dietary supplement* —

“(1) means a product (other than tobacco) intended to supplement the diet that bears or contains one or more of the following dietary ingredients: (A) a vitamin; (B) a mineral; (C) an herb or other botanical; (D) an amino acid; (E) a dietary substance for use by man to supplement the diet by increasing the total dietary intake; or (F) a concentrate, metabolite, constituent,
extract, or combination of any ingredient described in clause (A), (B), (C), (D), or (E);

(2) means a product that (A)(i) is intended for ingestion in a form described in section 411(c)(1)(B)(i) [of the Act]; or (ii) complies with section 411(c)(1)(B)(ii); (B) is not represented for use as a conventional food or as a sole item of a meal or the diet; and (C) is labeled as a dietary supplement; and

(3) does (A) include an article that is approved as a new drug under section 505 [of the Act] or licensed as a biologic under section 351 of the Public Health Service Act (42 U.S.C. 262) and was, prior to such approval, certification, or license, marketed as a dietary supplement or as a food unless [FDA] has issued a regulation, after notice and comment, finding that the article, when used as or in a dietary supplement under the conditions of use and dosages set forth in the labeling for such dietary supplement, is unlawful under section 402(f) [of the Act]; and (B) not include (i) an article that is approved as a new drug under section 505 [of the Act], certified as an antibiotic under section 507 [of the Act], or licensed as a biologic under section 351 of the Public Health Service Act (42 U.S.C. 262), or (ii) an article authorized for investigation as a new drug, antibiotic, or biological for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public, which was not before such approval, certification, licensing, or authorization marketed as a dietary supplement or as a food unless [FDA], in [its] discretion, has issued a regulation, after notice and comment, finding that the article would be lawful under this Act. Except for purposes of section 201(g), a dietary supplement shall be deemed to be a food within the meaning of this Act.”

**Dosage Form:** A pharmaceutical product type, for example, tablet, capsule, solution, or cream, that contains a drug ingredient (substance) generally, but not necessarily, in association with excipients

**Drug:** The following definition is taken directly from 21 U.S.C. 321(g)(1). The term drug means “(A) articles recognized in the official United States Pharmacopoeia, official Homeopathic Pharmacopeia of the United States, or official National Formulary, or any supplement to any of them; and (B) articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals; and (C) articles (other than food) intended to affect the structure or any function of the body of man or other animals; and (D) articles intended for use as a component of any articles specified in clause (A), (B), or (C). A food or dietary supplement for which a claim, subject to sections 403(r)(1)(B) and 403(r)(3) [of the Act] or sections 403(r)(1)(B) and (r)(5)(D), is made in accordance with the requirements of section 403(r) is not a drug solely because the label or the labeling contains such a claim. A food, dietary ingredient, or dietary supplement for which a truthful and not misleading statement is made in accordance with section 403(r)(6) is not a drug under clause (C) solely because the label or the labeling contains such a statement.”

**Drug Product:** A finished dosage form, for example, tablet, capsule, solution, etc. (21 CFR 210.3 (b)(4))

**Drug Substance:** An active ingredient that is intended for use to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure or any function of the human body (21 CFR 314.3(b))
Food: The term *food* means (1) articles used for food or drink, (2) chewing gum, and (3) articles used for components of such articles (21 U.S.C. 321(f)).

Formulation: A formula that lists the components (or ingredients) and composition of the dosage form. The components and composition of a multi-herb botanical drug substance should be part of the total formulation.

Marker: A chemical constituent of a botanical raw material, drug substance, or drug product that is used for identification and/or quality control purposes, especially when the active constituents are not known or identified.

Multi-Herb (Botanical Drug) Substance or Product: A botanical drug substance or drug product that is derived from more than one botanical raw material, each of which is considered a botanical ingredient. A multi-herb botanical drug substance may be prepared by processing together two or more botanical raw materials, or by combining two or more single-herb botanical drug substances that have been individually processed from their corresponding raw materials. In the latter case, the individual single-herb botanical drug substances may be introduced simultaneously or at different stages during the manufacturing process of the dosage form.

Plant Material: A plant or plant part (e.g., bark, wood, leaves, stems, roots, flowers, fruits, seeds, or parts thereof) as well as exudates thereof.

Single-Herb (Botanical Drug) Substance or Product: A botanical drug substance or drug product that is derived from one botanical raw material. Therefore, a single-herb substance or product generally contains only one botanical ingredient.

Spectroscopic and/or Chromatographic Fingerprint: A spectroscopic and/or chromatographic profile of a botanical raw material, drug substance, or drug product that is matched qualitatively and quantitatively against that of a reference sample or standard to ensure the identity and quality of a batch and consistency from batch to batch.
QUESTIONS AND ANSWERS

Q1: Are INDs required for clinical studies of botanical products that are lawfully marketed as dietary supplements in the United States?

A1: It depends on what the botanical product is being studied for. If a lawfully marketed botanical dietary supplement is studied for a dietary supplement use, i.e., effect on the structure and/or a function of the body, an IND is not required (see final rule on “Structure and Function Claims for Dietary Supplements,” 65 FR 1000, January 6, 2000). Although an IND is not legally required for such a study, CDER encourages sponsors to submit one. If you have questions on how to design such a study, FDA would be willing to review and provide advice on protocols. You may contact CDER’s Botanical Review Team at 301-827-2250 or BOTANICALTEAM@ceder.fda.gov. If a botanical preparation is being studied for its effects on a disease in the proposed investigation (i.e., to cure, treat, mitigate, prevent, or diagnose disease, including its associated symptoms), it is considered a new drug and will need to be studied under an IND (see § 312.2).

Q2: Are INDs required for clinical studies on marketed dietary supplements for research purposes only?

A2: Again, it depends on the use. If the intent is to study the effect of the product on the structure and/or a function of the body, no IND is needed. If the study is to assess the effects on disease, an IND is needed.

Q3: Is there any other setting in which an IND is not required for the botanical study?

A3: When a nonmarketed botanical preparation is studied in the United States for a dietary supplement use, an IND is not required. In addition, clinical studies conducted in foreign countries require no IND. However, FDA will accept an IND for either kind of study. In the absence of an IND, an investigational new drug intended for export for the purpose of clinical investigation must comply with the requirements set forth in § 312.110(b)(2) unless the new drug has been approved or authorized for export under section 802 of the Act (21 U.S.C. 382).

Q4: May a sponsor submit an IND for a phase 3 study of a botanical product not previously studied under an IND?

A4: Yes. Clinical data collected from phase 1 and phase 2 studies conducted without an IND can be used to support a phase 3 study involving the same drug substance if they are adequately designed and conducted. The formulation/dosage form of the botanical product used in the proposed phase 3 study ideally would be the same as that of the product used in phase 1 and 2 studies as well as in the preclinical (nonclinical) studies. If the product is different, additional studies may be appropriate.

Q5: For NDA approvals of botanical drug products, must all studies be carried out under
INDs?

A5: No. FDA does not require that all studies submitted in an NDA be conducted under an IND. Clinical studies need not necessarily be conducted under an IND (i.e., if they are carried out abroad). The clinical data generated from these studies conducted without an IND can be used to support an NDA if the studies were adequately designed and conducted under good clinical practices.

Although an IND is not required by law in all cases, the sponsor is encouraged to go through the IND process. Compliance with the IND requirements will help to ensure that an adequate pharmaceutical product development program is in place so that the material will meet the quality standards not only for various phases of clinical trials but also for eventual marketing. It will also help to ensure that the clinical trials will be well designed so that data generated can be persuasive.

Q6: It appears that the changes in regulatory approaches described in the guidance on Botanical Drug Products concern only IND applications. How will these changes be applied to the NDA requirements for botanical drugs?

A6: To facilitate the clinical development of botanical drugs, FDA decided to focus initially on a guidance for INDs, especially the early phases of clinical study. The standards for the safety and efficacy required for marketing approval of a botanical drug are the same as those required for a conventional chemical drug for the same indication. However, the product quality standards for a botanical drug can be different from those for a purified chemical drug. The Botanical Drug Products guidance contains recommendations for establishing appropriate quality standards for botanical drugs.

Q7: Some botanical preparations are not administered orally, e.g., intravenous, topical, and inhalation products. How are these nonoral formulations considered in the guidance?

A7: The guidance applies to all dosage forms of botanical products. All parenteral, topical, inhalation, or other nonorally administered botanical products are considered to be drugs, not dietary supplements, and must be studied under an IND for any use (see section 201(ff) of the Act). Just as for purified chemical drugs, the type of quality testing varies from dosage form to dosage form. For example, all injectables are required to be sterile and pyrogen-free (211.165(b) and 211.167 and 314.50(d)(1)(ii)(b); oral tablets are not. In addition, dietary supplements are orally ingested and the human experience of an orally administered botanical dietary supplement may not be applicable to the same botanical product given through other routes.

Q8: In terms of IND requirements and regulatory review by the Agency, is there any difference between a commercial development program and an academic research project?

A8: No. The Agency applies the same standards to both commercial and academic sponsors when evaluating the safety and quality of human studies proposed in INDs.
Q9: Intellectual property rights are a difficult issue for developing new drugs from well-known botanical preparations. How does FDA protect the confidentiality of a sponsor’s submission? What kind of IND/NDA data may FDA release without prior permission from the sponsor?

A9: IND information generally is not publicly available (see §§ 312.130, 314.430). Once an NDA is approved, FDA may release certain safety and efficacy information (§ 314.430(e)). Manufacturing information (including information related to growers and suppliers) provided in an NDA or a Drug Master File (DMF) is considered proprietary and may not be released (21 U.S.C. 331(j); 21 CFR 20.61).

Q10: How does FDA ensure that the new Botanical Drug Products guidance will be implemented consistently across the different new drug review divisions?

A10: FDA will provide reviewers in all divisions with training on how to implement the guidance.

Q11: One of the major premises of the new guidance is that because many botanical products have been used by a large population for a long period of time, they are presumed to be safe enough to be studied in clinical trials without first undergoing conventional nonclinical studies. What kind of documentation should a sponsor submit to demonstrate prior human experience with the sponsor’s product?

A:11 The Agency recognizes that prior human experience with a botanical product can be documented in many different forms and sources, some of which may not meet the quality standards of modern scientific testing. The sponsor is encouraged to provide as much data as possible, and the review team for the botanical drug IND generally will accept all available information for regulatory consideration. FDA will assess the quality of the submitted data on a case-by-case basis. It should be emphasized that, in reviewing botanical drugs, the Agency does not lower or raise the safety and efficacy standards for marketing approval that apply to purified chemical drugs. The guidance simply recommends the use of different types of data for preliminary safety consideration of human trials (for example, large quantities of mostly anecdotal human data instead of animal studies).

Q12: In many cases, botanical therapies are highly individualized with variations in relative contents of multiple plant ingredients tailored for each patient. Must a sponsor submit a separate IND for every change in composition, if similar patients are being treated for the same indication?

A12: Studies can be designed to take into account individualized treatments. Multiple formulations can be included in one IND if they are being studied under a single clinical trial. It is important that the IND provide the rationale for using multiple formulations and the criteria used to assign patients to different treatment regimens.

Q13: Many medicinal plants with therapeutical potential are quite toxic. Does the new
guidance address the study of such botanicals?

A13: The guidance discusses this issue in the sections addressing botanical drug products with known safety issues (e.g., section VI.A). Well-known examples of safety issues concerning botanicals include the nephrotoxicity associated with herbal preparations containing aristolochic acid and the hepatotoxicity associated with comfrey products containing pyrrolizidine alkaloid. Other examples include the cardiovascular and central nervous system effects associated with yohimbe and the hepatotoxicity associated with germander and chapparal. In such cases, FDA will evaluate the known risk and the potential benefit of an investigational drug for its intended use. When the potential benefit of an investigational drug outweighs its risk in the intended patient population, clinical trials may be allowed to proceed under an IND (see § 312.42). For example, FDA will accept a relatively higher level of toxicity of an investigational drug when studied to treat terminally ill cancer patients. However, additional nonclinical studies may be appropriate to adequately characterize the toxicity (e.g., can a dose be identified that would not be expected to produce toxicity?) and/or additional monitoring may be appropriate during the clinical trial. Also, FDA may recommend against human studies (e.g., bioavailability, clinical pharmacology) in healthy volunteers.

Q14: There is a concern that if a botanical is being studied under an IND or is approved as a new drug in an NDA, its subsequent status as a dietary supplement may be jeopardized. Is this true?

A14: No, it is generally not true for products already on the market before approval of an NDA. It is also generally not true for products marketed before authorization of an IND for which substantial clinical investigations have been instituted and the existence of such investigations has been made public (see section 201(ff)(3) of the Act).

Q15: What is FDA’s advice on the initial approach for sponsors not familiar with new drug development and regulatory processes?

A15: A sponsor should first consult the guidance. If there are questions concerning the guidance document or other questions about the submission of INDs for botanical drugs, consult the appropriate CDER review division for the therapeutic class of the sponsor’s product. CDER also grants pre-IND meetings with sponsors.

Q16: The guidance states that the submission of an NDA for a drug derived from plants taken from the wild is an extraordinary circumstance requiring the submission of an environmental assessment (EA) under § 25.21. Are plants maintained in their native setting on private land considered wild?

A16: Yes. Plants that are obtained from their native setting on either public or private land are considered to be taken from the wild. Cultivated plants are considered those that are grown collectively in controlled settings such as plantations, farms, or greenhouses, i.e., purposely segregated from wildlife to the extent practicable.
Q17: *Is a drug made with a commercially available crude extract viewed the same as a drug derived from plants taken from the wild for purposes of determining the need for an EA?*

A17: Yes. If an NDA is submitted for a drug made from a crude extract or intermediate from a plant taken from the wild, an EA is required under § 25.21. This is true whether or not the extract or intermediate is commercially available. As for an IND for a drug made from a crude extract or intermediate from a plant taken from the wild, FDA will decide on a case-by-case whether an EA is required.

Q18: *What is the GMP status of botanical raw materials (starting materials) in terms of compliance and inspection?*

A18: Starting materials of botanical origin that are used to produce a botanical drug substance should be evaluated for quality. The use of appropriate starting materials and the drug substance manufacturer’s ability to control the source depend on appropriate specifications (tests, analytical procedures, and acceptance criteria). In addition to establishing specifications, manufacturers can achieve adequate quality control of starting materials by applying the principles outlined in FDA’s botanical guidance and by following good agricultural and good collection practice for starting materials of herbal origin (e.g., European Medicines Evaluation Agency HMPWP/31/99). Upon receipt of the starting materials at a processing facility, it is the responsibility of the drug substance manufacturer to determine the suitability of these raw materials before use. This can be accomplished by examining and/or testing to ensure that the acceptance criteria are met and by documenting the quality control for the processing of the starting materials. FDA will review the inspection and examination of starting materials upon receipt when conducting a current good manufacturing practice (CGMP) inspection of a drug substance manufacturer.

Q19: *Will FDA assign the same level of priority to botanical drug products as to other drugs with respect to meeting with IND sponsors and NDA applicants?*

A19: Yes, FDA treats botanical and purified chemical drugs the same.
ATTACHMENT B: INFORMATION TO BE PROVIDED IN AN IND FOR A BOTANICAL DRUG

IND for a Botanical Drug Product

General principles; format and contents
(Sec. VI)

Initial clinical trial of a marketed botanical product with no known safety issues
(Sec. VII)

Documentation of use; limited CMC information; previous human experience may be sufficient to support safety

Initial clinical trial of a nonmarketed botanical product or a marketed botanical product with known safety issues
(Sec. VIII)

More documentation of use and more CMC information than in Sec. VII

Expanded clinical trial of any botanical product
(Sec. IX)

Same documentation of use but more detailed CMC information than in Sec. VIII; standard nonclinical toxicology studies may be needed

Is the product a traditional preparation?

Yes

Previous human experience may be sufficient to support safety
(Sec. VIII.C.1)

If the product is marketed only outside the U.S., additional CMC and nonclinical safety information may be needed
(Sec. VII.B.1, B.3.c, & C.2)

No

Additional nonclinical safety information may be needed
(Sec. VIII.C.2)